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V. Summary
Influenza A virus (IAV) infection can cause severe pneumonia and lead to acute 
respiratory distress syndrome and ultimately death. Despite damage by viral 
replication, imbalanced production of anti-viral cytokines (“cytokine storm”) resulting 
in inflammation can also lead to severe lung destruction. Therapeutics as vaccines 
and anti-viral drugs target components of the virus itself resulting in resistant 
variants. Therefore new therapeutic measures are urgently needed. IAV has been 
shown to activate the NF-B and MAPK (Raf/EK/ERK) signalling pathway. These 
pathways seem to have both pro- and anti-viral effects, by promoting nuclear export 
of the viral genome and by inducing expression of anti-viral pro-inflammatory factors.
Therefore it was postulated that the inhibition of these signalling pathways will 
simultaneously reduce virus replication as well as modulate cytokine production 
without affecting host defence.
Using specific IKK- (Bay-11-7082) and MEK- (U0126) inhibitors at non-toxic 
concentrations, I analysed the effect of NF-B and MAPK pathway inhibition on 
propagation of a highly pathogenic avian influenza virus (strain A/FPV/Bratislava/79, 
H7N7) and a human influenza virus (strain A/PR/8/34, H1N1) and the virus-induced 
cytokine induction in infected human lung epithelia cells (A549) and mice primary 
alveolar epithelial cells (AECs), in vitro. Experiments were also performed in an in 
vivo mouse model for “proof of principle” applying the above inhibitors and the 
A/PR/8/34 virus for infection.
Results show, (1) by western blot and transcription factor assay that both pathways 
(NF-B and MAPK) are activated upon IAV infection in A549 cells; (2) that both 
inhibitors (IKK-, MEK-inhibitor), used at non-toxic concentrations, lead to decrease in 
signalling, virus titres (FFU assay) and (3) reduced cytokine expression (multiplex 
cytokine assay and ELISA), in vitro (A549 and AECs) as well as in vivo (mice). I also 
observed differences in the virus-induced (FPV and PR8) cytokine release when 
comparing different cell types (A549, AECs) as well as in the mouse model.
The results demonstrate that inhibition of NF-B and Raf/MEK/ERK pathway can be 
used to simultaneously reduce virus titres and modulate pro-inflammatory cytokine 
expression in vitro as well as in vivo. This could be of importance for future 
therapeutic strategies to treat influenza pneumonia and virus induced “Cytokine
Storm”.
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VI. Zusammenfassung
Eine Infektion mit dem Influenza A virus (IAV) kann schwere Pneumonien 
verursachen, die zum akuten Atemnotsyndrom und schließlich zum Tod führen 
können. Neben der Schädigung durch die virale Replikation, kann auch die in einer 
überschießende Entzündung resultierende, ungeregelte Produktion von anti-viralen 
Zytokinen („Zytokinsturm“), zu einer ernsthaften Schädigung der Lunge führen. 
Impfstoffe und anti-virale Substanzen als Therapeutika richten sich in der Regel 
gegen bestimmte virale Funktionen und Virusbestandteile und führen somit schnell 
zu Resistenzen. Daher sind neue therapeutische Möglichkeiten dringend notwendig. 
Es konnte bereits nachgewiesen werden, dass IAV den NF-B und den MAPK 
(Raf/MEK/ERK) Signalweg aktivieren. Diese Signalwege scheinen beide, durch die 
gleichzeitige Förderung des Kernexports des viralen Genoms und der 
Expressionsregulation von anti-viralen pro-inflammatorischen Faktoren, pro-und anti-
virale Effekte zu besitzen. Daher wurde postuliert, dass durch die Hemmung dieser 
Signalwege sowohl die Virusvermehrung reduziert werden kann, als auch die 
Zytokinproduktion moduliert werden kann bei gleichzeitigen Erhalt der Wirstabwehr.
Unter Verwendung spezifischer Inhibitoren beider Signalwege (IKK-Inhibitor: Bay-11-
7082, MEK-Inhibitor: U0126) in nicht-toxischen Konzentrationen analysierte ich in 
vitro den Effekt der NF-B- und MAPK-Signalwegsinhibition in Bezug auf die 
Vermehrung, eines hochpathogenen aviärern Influenzavirus (HPAIV, Stamm 
A/FPV/Bratislava/79, H7N7) und eines humanen Influenzavirus (Stamm A/PR/8/34, 
H1N1), sowie die Zytokininduktion in infizierten humanen Lungenepithelzellen (A549) 
und alveolären primären Mäuseepithelzellen (AECs). Auch wurden zur Bestätigung 
der Hypothese in einem Modelorganismus diese Experimente unter Verwendung der 
oben genannten Inhibitoren und des A/PR/8/34 Virus in einem Mausmodell in vivo
durchgeführt. 
Die Resultate zeigten, dass (1) beide Signalwege (NF-B und MAPK) durch die IAV 
Infektion von A549-Zellen aktiviert werden – nachgewiesen durch Westernblot-
Analysen und Messung der Transkriptionsfaktor-Aktivierung, (2) beide Inhibitoren 
(IKK-, MEK-Inhibitor) unter Verwendung in nicht-toxischer Konzentrationen zur 
Verringerung des Virustiters führen (FFU-Assay) und (3) die Zytokinexpression 
(„multiplex cytokine assay“ und ELISA) in vitro (A549 und AECs), sowie in vivo
(Mausmodel) verringert ist. Dabei konnte gezeigt werden, dass die Zytokininduktion 
abhängig ist vom (1) Zellmodel (A549 oder AECs) oder Mausmodel und (2) vom 
Virusstamm (FPV oder PR8)
Die Resultate demonstrieren, dass die Inhibition der NF-B und Raf/MEK/ERK-
Signalwege dazu verwendet werden können gleichzeitig Virustiter zu reduzieren und 
pro-inflammatorische Zytokinexpression in vitro, sowie in vivo zu beeinflussen. Dies 
könnte zukünftig für die Behandlung von Influenzapneumonien im Bezug auf die 
Hemmung der Virusvermehrung und Modulation der virusinduzierten 
Zytokinausschüttung von großer Bedeutung sein.  
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1. Introduction
1.1. Influenza viruses
1.1.1. Different types of influenza viruses
Influenza viruses belong to the family of the Orthomyxoviridae and are subdivided 
into three genera depending on the antigenic differences of their nucleo- and matrix 
proteins: type A, B and C. They also differ with respect to host range, variability of the 
surface glycoproteins, genome organization and morphology. The influenza A viruses 
are responsible for major pandemic outbreaks of influenza and for most of the well-
known annual flu epidemics. Influenza C is different from the A and B type, and 
generally causes only mild cold-type disease in humans. Type A influenza viruses 
can infect in general birds and mammals (Figure 1.1), whereas type B and C 
influenza viruses are normally only found in humans. The primary reservoir of all 
influenza A viruses are wild aquatic birds. Type A influenza viruses are further 
classified into subtypes based on two surface glycoproteins of the virus; the 
haemagglutinin (HA: H1-H16) and the neuraminidase (NA: N1-N9) proteins. Unlike 
influenza A viruses, type B and C influenza viruses are not classified into subtypes
[1].
Figure 1.1: The reservoir of influenza A viruses. The hypothesis is that wild aquatic birds are the 
primordial reservoir of all influenza viruses for avian and mammalian species. Direct transmission of 
influenza between pigs and humans has been shown (solid line). There is also extensive evidence for 
transmission between wild ducks and other species. The five different host groups are based on 
phylogenetic analysis of the nucleoproteins of a large number of different influenza viruses (adapted 
from: Webster,[2]).
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1.1.2. Influenza A virus
1.1.2.1. Morphology and genome structure of influenza A virus
Influenza A viruses (IAVs) are enveloped viruses and consist of eight segmented 
single-stranded RNAs of negative polarity with between 890 to 2341 nucleotides 
each that code for at least 10 viral proteins [1, 3] (Figure 1.2 and Table 1.1). 
Influenza A viruses particles are pleomorphic, in general spherical and have a size of 
approximately 80 to 120 nm in diameter [1].
The lipid envelope is derived from the host cell membrane during viral budding from 
cell surface  and consists of a lipid bilayer presenting spike-like projections (about 
500) on the outside, which represent the structural glycoproteins HA 
(haemagglutinin) and NA (neuraminidase). The matrix protein M1 underlies the 
inside, and the M2 (ion channel) protein is also a trans-membrane protein and is 
found in the lipid bilayer of the viral envelope [1, 3, 4].
The viral HA is a trimer, which comprises three individual HA monomers, whereas the 
NA is a tetramer. HA is five times more abundant than NA [5]. The HA is synthesized 
as a single polypeptide chain (HA0), which is subsequently cleaved into two subunits, 
HA1 and HA2 [5-10]. Cleavage of HA0 is essential for the molecule to be able to 
mediate membrane fusion between the viral envelope and the host cell membrane
and for infectivity [5, 8, 11]. HA1 and HA2 appear as two distinct subunits, with HA1 
being the globular domain at the distal end of the spike, which is responsible for 
binding of the virus to the cellular sialic acid receptor [5]. HA1 is also responsible for 
the major antigenic epitopes of the molecule to which the host will direct a
neutralizing antibody response [6, 8]. The HA2 forms the stem of the viral spike and 
contains a conserved region of 20-amino acid residues, mostly hydrophobic at the N-
terminus [5, 8]. This sequence is generally referred to as the “fusion peptide”, and is
responsible for triggering the fusion between the viral envelope and the host cell 
membrane [5, 8, 9].
The NA is the second major surface antigen of the virus and plays an important role 
in efficient viral budding [2, 4, 5]. It displays enzymatic activity towards a terminal 
sialic acid and an adjacent sugar residue [5]. Since sialic acid receptors are present 
on the cell surface, the neuraminidase activity of NA permits release and prevents 
reattachment or aggregation, of the newly formed virions from the surface of the 
infected cells [2, 4, 5].
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Figure 1.2.A: Cartoon of the influenza virion. The eight viral RNA segments were separated by 
electrophoresis (left). The corresponding gene products and their localization within the virus particle 
are depicted on the right. The only non-structural virus protein, the NS1, is only found inside infected 
cells. (Adapted from Ludwig et al.[12])
Table 1.1.: Influenza A virus proteins and functions (strain A/PR/8/34, H1N1)
(Modified from Ludwig et al. [13])
Segment vRNA (nt) Protein AA Functions
1 2341 PB2 759 subunit of  RDRP; "Cap-snatching"
2 2341 PB1
PB1-F2
757
87
catalytic subunit of  RDRP; elongation
apoptosis?
3 2233 PA 716 subunit of  RDRP
4 1778 HA 566 haemagglutinin; surface-glycoprotein; 
receptor binding; membrane fusion
5 1565 NP 498 nucleoprotein; encapsidation of vRNA and cRNA; part of 
transcriptase complex; nuclear/cytoplasmic transport of vRNA
6 1413 NA 454 neuraminidase; surface-glycoprotein; 
receptor disruption, virus releasing
7 1027 M1
M2
252
97
matrix protein
ion channel activity ; protecting HA-conformation
8 890 NS1
NEP/NS2
230
121
post-transcription regulator; inhibition of (i) pre-mRMA 
splicing, (ii) polyadenylation (iii) PKR-activation
nuclear export factor
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Oseltamivir (Tamiflu) and zanamivir (Relenza) are neuraminidase inhibitors (NAI) and 
the only two approved NAI in humans. These drugs are sialic acid analogues, which 
inhibit the enzymatic activity of NA, thus slowing down the release of progeny virions 
from infected cells [12, 14, 15].
A third integral membrane protein, the M2, forms a homotetramer and is expressed 
on the virus surface. M2 functions as a pH-activated proton channel and is essential 
for viral uncoating in the viral infection cycle [1, 5, 16, 17]. It permits entry of protons 
from the endosome into the viral particle, thereby weakening and disrupting the 
interaction between the viral genome and the M1 protein [1, 5]. M2 also seems to be 
important for viruses with intracellular cleaved HAs (such as H5 and H7 subtypes of 
avian viruses) by regulating the intra-compartmental pH in the trans Golgi network 
(TGN) above the threshold at which conformational changes of the HA occur [1, 5].
M2 is the target for the influenza drugs amantadine and rimantadine [17]. Blocking of 
the M2 channel with amantadine slows the dissociation of M1 from ribonucleoprotein 
complexes (RNPs) (see below) and the viral membrane, inhibiting subsequent steps 
in the viral life cycle [1, 5, 17].
Influenza A and B virus genomes consist of eight negative-sense single-stranded 
RNAs. The viral RNA is assembled with the viral RNA-dependent RNA-polymerase 
(RDRP), which is itself a complex of three subunits: PB1, PB2 and PA, and the 
nucleocapsid protein NP to form ribonucleoprotein complexes (RNPs) [1, 5] (Figure 
1.2.B). The main function of NP is to encapsidates the virus genome, leading to RNA 
transcription, replication and packaging [18]. The RNPs are surrounded by a layer of 
the matrix protein, M1, which is the most abundant structural protein of influenza 
virus and is thought to act as an adaptor protein between the lipid envelope and the 
internal RNP particles [19].
All viral segments encode for one protein except for segment 7 and 8 which have 
overlapping reading frames and will give rise to the proteins M1, M2 and NS1, NS2 
(also called nuclear export protein NEP) respectively, by splicing of the primary 
mRNA transcript [5] (Figure 1.2. and Table 1.1.). Also, some influenza viruses 
encode for another protein, PB1-F2, in the +1 reading frame of the PB1 gene [20].
M1 protein associates tightly with the vRNP both in the virion as well as during virus 
assembly in the infected cell [19, 21, 22]. After the protons have entered the virion via 
the M2, the M1 is released from the RNPs, and the RNPs are then rapidly imported 
from the virion, which has fused with the endosomal membrane, into the nucleus, by 
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an active mechanism, through the nuclear pore complexes (NPC) [23]. The M1 
protein association to vRNP has been shown to be important also for nuclear RNP
export, late in the replication cycle, and this association also seems to prevent the re-
import of the newly synthesized vRNPs back into the nucleus [22-24].
NS2 is present in low copies in the virion, whereas the NS1 is the only true non 
structural protein, but it is highly abundant inside infected cells [5].
Figure 1.2.B: The influenza virus RNP structure. The NP (blue) is associated with (-) sense single-
stranded RNA (black line), and the three subunits of RNA-dependent RNA-polymerase (RDRP): PB1 
(yellow), PB2 (orange) and PA (green), which bind at a short duplex region of the vRNA. (Adapted 
from Portela and Digard, [18])
1.1.2.2. Propagation and genome replication of influenza A virus
Influenza viruses bind to sialic acid residues that are ubiquitously present on 
glycoproteins or glycolipids on the host cell surface [1, 4] (Figure 1.3). The main 
targets of IAV in humans are epithelial cells of the upper and lower respiratory tract, 
but they can also infect macrophages, dendritic cells and other leukocytes [25]. The 
virus binds to the cell via its receptor-binding pocket at the conserved distal tip of the 
HA molecule [8]. Different IAV HAs show different receptor binding specificities 
depending on the nature of the glycosidic linkage between the terminal sialic acid 
and the penultimate galactose residue on the carbohydrate side chains on the 
receptor [8]. Human influenza viruses preferentially bind to sialic acids attached to 
galactose in 2,6 configuration, whereas avian viruses have a preference for sialic 
acids attached to galactose in an 2,3 linkage [8, 26-29]. In humans influenza viruses 
infection is mainly a respiratory disease and the sialic acid 2,6 linkage is abundant 
in the lungs, whereas in birds it is enteric and the sialic acid 2,3 linkage is mainly 
found in the intestine. This difference is thought to be the basis for the restriction in 
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transmission of avian influenza viruses directly to humans [8]. On the other hand, 
pigs have receptors with both type of linkage between sialic acid and galactose, and 
therefore are susceptible to infection with either human or avian viruses. Co-infection 
of pigs with different influenza viruses is considered one way by which new viruses 
with pandemic potential may arise [8, 26]. 
Virus binding to receptors initiates uptake through so-called receptor-mediated 
endocytosis. In this process, virus particles are internalised by the host cell plasma 
membrane. The vesicles thus formed subsequently fuse with intracellular 
compartments called endosomes, which progress from mild acidic to late endosomes 
with decreasing internal pH. One of the important steps in IAV infection is the fusion 
reaction between the viral envelope and the endosomal membrane. For this, the 
maintenance of a low pH inside the endosomes (pH5-6), by proton pumps within the 
endosomal membrane, is of utmost importance. Upon pH decrease the HA suffers a 
major conformational change in its structure thereby leading to movement of the 
fusion peptide sequences of HA2, previously buried within the stem of the HA trimer, 
to the distal tip of the HA spike, allowing their insertion into the target membrane 
(Figure 1.3) [8-10]. This then allows for merging of the two membranes, through 
which the viral core penetrates into the cell cytosol [30, 31]. M2 proton channel
activity is required for the uncoating process. M2 facilitates the flow of ions from the 
endosome into the virion interior, leading to disruption of protein-protein interactions, 
thus dissociating M1 from RNPs and viral membrane [1, 5].
The RNP complexes released into the host cell cytosol are transported intact to the 
nucleus, through the nuclear pore complex (NPC). All four proteins of the RNP 
complex (NP, PB1, PB2 and PA) contain nuclear localization signals (NLS) and are 
actively transported into the nucleus, where replication and transcription of viral RNA 
(vRNA) takes place (Figure 1.3 and 1.6) whereas M1 may enter the nucleus by 
passive diffusion because of its small size [32-36]. In the nucleus the negative (-) 
sense vRNAs are transcribed to positive (+) sense messenger RNAs (mRNAs) by the 
replicase/transcriptase RDRP (PB1, PB2 and PA) carried with the RNPs (Figure 1.3 
and 1.6). For initiation of viral mRNA synthesis, in a process referred to as “cap 
snatching”, the viral transcriptase “steals”, by endonucleolytic cleavage, short cap 
regions (m7GpppNm) from cellular pre-mRNAs, to act as primers. Thus, this cap 
snatching process, which is later required for efficient binding of ribosomes to the 
mRNA, favours production of viral components over synthesis of cellular proteins. 
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After priming synthesis of mRNAs are terminated 17 to 22nt from the 5’ end of the 
vRNA template at a sequence of 4/5 to 7 uridines (U) [1, 5]. This stretch of uridines 
act as a polyadenylation signal [37-39] which leads to synthesis of a poly(A) tail by 
the viral RNA polymerase, by repeated copying of the U sequence, and added to the 
3’end of the viral mRNA [38, 39]. The mRNAs are then transported to the cell cytosol 
for translation to occur [1, 5]. 
Adsorption
Endocytose
Fusion and
Uncoating
vRNA (-)
cRNA (+)
mRNA
Import
Translation
Posttranslational
Processing
RNP-
Export
Budding
Packaging
Figure 1.3: The Replication cycle of influenza virus. It begins with binding of the HA-spike to sialic-
acid containing receptors on the cell surface. The virion is then taken up into the cell through 
endocytosis. The RNPs are released into the cell cytoplasm after fusion between the viral and the 
endosomal membrane, and then transported into the nucleus, where transcription and replication of 
the viral RNA takes place. Viral mRNA is exported to the cytoplasm and translated into viral proteins. 
Some replicative proteins (i.e. NP, PB1, PB2 and PA) are transported back to the nucleus and 
continue the viral genome replication. Viral surface-glycoproteins (i.e. HA and NA) are transported to 
the cell surface. Late during virus replication cycle, vRNPs are exported out of the nucleus and packed 
and progeny virions are then released from the membrane by budding. (Adapted from Pleschka)
As mentioned above the polymerase proteins (PB1, PB2 and PA) are required for 
this process. The PB1 subunit forms the core of the complex and is responsible for 
polymerase activity, whereas the PB2 subunit is involved in generation of capped 
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RNA primers for the initiation of transcription by binding the cap structures of host 
pre-mRNA (cap snatching) prior to their endonucleolytic cleavage by PB1 [1, 2, 5]. 
The PA subunit is required for both transcription and replication, but its exact role in 
the virus replication cycle is still unclear [2, 40].
(-) sense viral RNAs (vRNA) also serve as templates for production of exact copies of 
complementary (+) sense RNA (cRNA), which in turn lead to synthesis of more vRNA 
molecules [1, 5, 41]. For synthesis of both cRNA (template) and full-length copies of 
vRNA molecules, initiation is achieved in a primer-independent manner, resulting in 
triphosphorylated 5’ ends. During cRNA synthesis, the polyadenylation signal is 
ignored [1, 5, 18, 41]. Encapsidation of cRNAs and vRNAs by the NP is a 
prerequisite for them to be recognized as templates for the viral polymerase. These 
newly formed vRNAs are later transported into the cytoplasm as vRNPs for assembly 
into new virus particles [18]. 
After translation, proteins may remain in the cytoplasm or become associated with 
the cell membrane. PB1, PB2, PA and NP proteins migrate back into the nucleus, 
where they associate with newly-synthesized vRNA to form new RNP complexes. NP 
is thought to control whether mRNA or cRNA are produced, i.e. later in infection 
when there is a high amount of NP, mRNA synthesis stops whereas cRNA synthesis 
continues. The amount of free NP is therefore important for switching between 
expression and assembly during the viral replication cycle [18]. Also, in the nucleus 
M1 and NS2/NEP bind to the RNPs and are exported through the nuclear pore 
complexes (NPCs) into the cytosol. Nuclear export of RNPs has been proposed to 
depend on several viral proteins, such as viral M1 and NEP, and on cellular factors 
CRM1 and Ran-GTP [22, 32, 42-44]. The M1 retains the RNPs in the cytoplasm for 
the further maturation [32]. Consequently RNP associates with viral membrane 
proteins and together are released by budding outwards [5].
During synthesis of viral envelope proteins HA, NA and M2 which starts in the 
cytosol, the growing polypeptide chains are transported into the endoplasmic 
reticulum (ER), where the proteins are folded and assembled into trimmers and 
tetramers. Still in the ER, glycosylation of HA and NA begins, and they are 
subsequently transported through the Golgi apparatus and the trans-Golgi network 
(TGN) to the plasma membrane. Many modifications, such as polypeptide folding
[45], trimerization [46], N-glycosylation [47], acylation [48] and proteolytic cleavage
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[49]  are introduced along this pathway, until they reach the cell surface [50]. 
Normally different proteases are able to cleave the HA0 but this seems to depend on 
the amino acid (aa) sequence at the HA0 cleavage site. It has been proposed that 
the HA cleavage site would correlate with the virulence of the virus and that virulent 
strains (e.g. H5 and H7) would contain a recognition motif of the intracellular 
protease furin, whereas the avirulent strains would contain only a single arginine 
residue used by extra-cellular proteases [5, 8, 49]. Another important function of the 
M2 protein is noticeable at this stage. It protects the HA from a premature fusion-
activating conformational change, due to the mildly acidic pH inside the TGN. M2, 
through its proton channel activity can transiently neutralize the pH within the TGN [2, 
16].
1.1.2.3. Viral assembly and Budding
In polarized epithelial cells, HA and NA are transported to the apical side of the 
plasma membrane, resulting in release of progeny viruses back into the airways and 
not into the systemic circulation [1, 50]. After budding the viral HA interacts with the 
host cell receptor, at which point the NA cleaves off this bond and enables virus 
release from the infected cell and spread to other cells [51]. Sorting of the eight 
distinct genome segments into each particle is not a purely random process [52-54].
It seems that the packaging signal of vRNA molecules already occurs in the nucleus 
or during nuclear export through the process of vRNP/cRNP discrimination [55]. In 
support of this, another study showed that only vRNA molecules and no cRNA 
molecules are found outside the nucleus in the cytoplasm [56]. Another study 
suggests that the coding regions of viral RNAs possess signal sequences that 
promote recruitment of the segments during virion assembly [57]. In support of this 
theory, recent studies showed that RNPs of influenza A virus are organized in a 
distinct pattern (seven segments of different lengths surrounding a central segment). 
The individual segments are suspended from the interior of the viral envelope at the 
distal end of the budding virion and are orientated perpendicular to the budding tip
[52].
As mentioned before the NS1 protein is the only true non-structural protein. It is 
encoded by segment 8 (which is the shortest RNA segment) of the influenza A virus 
genome and seems to be extremely important in the pathogenesis of influenza A 
virus. It performs several functions and the list keeps growing. NS1 has been shown 
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to inhibit: splicing and polyadenylation of the cellular pre-mRNAs; end-formation of 
cellular mRNAs; nucleocytoplasmic export of cellular mRNAs; and in contrast to 
stimulate translation of viral mRNAs [58-65]. Due to the development of reverse 
genetics techniques, it has been possible to study in detail the function/s of the 
influenza A virus NS1 protein (NS1 mutants or a deleted NS1 gene – delNS1) [66]. It 
was interesting to note that the delNS1 virus was unable to replicate in most cells 
unless they were deficient for an interferon (IFN/) system and in wild type (wt)
mice the virus was unable to cause disease whereas in an IFN/ system deficient 
mouse strain (STAT1-/- mouse), the mice died [66, 67]. The influenza A NS1 has 
been shown to have ssRNA and dsRNA-binding activity, and as a consequence is 
able to sequester viral dsRNA and down-regulate the activation of dsRNA-activated 
protein kinase R (PKR), NF-B, IFN regulatory factor 3 (IRF-3) and the JNK effectors 
c-Jun and ATF-2 signalling pathway [63, 68-72]. By blocking activation of NF-B, 
IRF3 and AP-1 which together lead to IFN gene induction, IFNβ transcription is 
repressed [70-72]. PKR activation leads to inhibition of eIF-2 and therefore a 
reduction in protein synthesis. By inhibiting PKR activation the virus counteracts a 
blockage of protein synthesis, thereby sustaining its own replication [63, 68, 69]. 
IFNβ is one of the most potent antiviral cytokines [69], and will be further discussed 
later (cytokine interplay).
Other interesting studies have also shown that NS1 protein can down-regulate 
apoptosis, indicating anti-apoptotic properties [73].
1.1.3. Antigenic variation of influenza virus infection
Influenza A viruses can increase their antigenic diversity in two ways. It can change 
by “antigenic drift”, which occurs through small changes (mutations) in the virus HA 
or NA that happen continually over time due to single amino acid substitutions. This 
allows the virus to adapt to selective pressure as given by circulating neutralising 
antibodies [74, 75].
New virus strains arising from antigenic drift generally only result in epidemics and 
are not as severe, since partial immunity is present in persons with cross-reacting 
antibodies induced by previous infections.
Pandemics are due to the appearance of new influenza A subtypes against which the 
population has no previous immunity. This phenomenon is known as “antigenic shift”
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[76, 77]. The HA antigen is always involved in antigenic shift as it is responsible for 
eliciting virus-neutralizing antibodies [1-3]. The neuraminidase (NA) can also be 
affected. Concerning evidence from past pandemics, there are three possibilities as 
to how antigenic shift can occur (CDC, Focus on Bird Flu, 2005): (I) Reassortment: 
where the new virus subtypes are reassortant viruses resulting from double infection, 
in which eight RNA segments of different viruses swap with each other, producing a 
new virus. As already mentioned, pigs are thought to serve as a "mixing vessel" for 
AIV and human influenza virus where genetic reassortment may occur [78-82]. (II) 
Recirculation of pre-existing subtypes: where a limited number of influenza A 
subtypes would exist and be recycled in the human population when the antibody 
status of the population has fallen to levels which would allow for a pandemic 
infection; a cycle of approximately 70 years (CDC, Focus on Bird Flu, 2005). (III) 
Gradual adaptation of animal viruses to human transmission: evidence for this 
hypothesis is the 1918 pandemic. It seems that the pandemic virus was directly 
descended from an avian ancestor [83-85].
1.1.4. Avian influenza viruses
Even though influenza is thought of as a human disease, the natural reservoir for 
influenza A viruses (IAV) are aquatic birds and wildfowl. Many different strains 
actually circulate at any given time, although most don’t cause disease in wild birds. 
As mentioned before, influenza A viruses are divided into subtypes depending on the 
antigenic nature of the HA and NA proteins. So far 16 different HA and 9 different NA 
have been described for IAVs and only a limited subset are currently circulating in 
humans and are cause for annual epidemics and disease; subtypes H1N1, H3N2 
and H1N2. As expected they all originated from avian species and adapted to 
humans following zoonotic events [3, 86, 87].
Influenza viruses that infect birds are called “avian influenza viruses” (AIV).
In wild aquatic birds influenza infection does not cause disease but they can shed 
large amounts of the virus. In contrast, domestic poultry can develop severe 
symptoms and die from influenza infections [2].
1.1.4.1. History 
Avian influenza (AI) has become an international concern which has grown over the 
past years due mainly to the highly pathogenic avian influenza subtype (H5N1). 
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Serious outbreaks have affected almost all areas in Asia and recently also Europe
[88, 89]. AI was first recorded in Italy in 1878 as described by Perroncito et al. [90, 
91]. As it was the cause of massive poultry epidemics, this disease was then known 
as the “Fowl Plague”. In 1902 the causative agent was isolated from a chicken, 
marking the first documented isolation of influenza virus. The first human influenza 
virus isolation was demonstrated in 1933 [92]. In 1955, it was determined that the 
virus causing Fowl Plague was a type A influenza virus (http://avianflu.umd.edu/). 
1.1.4.2. Current situation (epidemics and pandemics)
AIV has had a devastating impact on the poultry industry throughout the world. In 
more recent years, east and Southeast Asian countries have been the most affected 
areas [93, 94]. Destruction of millions of poultry to prevent further spread has 
resulted in grave economic loses. The first outbreak of human illness due to H5N1 
AIV occurred in 1997 in Hong Kong with a mortality of 30% [95]. It was previously 
accepted that AIV could not directly infect humans, due to the different receptors 
present on either species and due to the receptor-binding specificities of avian and 
human viruses, as already explained [89]. However, a new strain of influenza virus 
can evolve by reassortment (rearrangement and swapping of genetic material when 
co-infected in the same host) [89, 96]. If this were to happen now, it could be 
devastating to the human population [79, 96, 97].
So far, the AIV that have been transmitted to humans are of subtypes H5, H7 and H9
[97]. These subtypes of avian influenza A viruses can be further classified as either 
highly pathogenic avian influenza (HPAI) or low pathogenic avian influenza (LPAI). 
So far, all outbreaks of the HPAI have been caused either by the H7 or the H5 virus 
subtypes [89, 97]. The subtype that has attracted the most attention more recently 
has been the H5N1, due to the deaths of many human lives [79, 80]. Although the 
incidence of H5N1 in Eastern Asia greatly increases the risk that it may evolve to a 
point where transmission between people might be possible, so far, there is no 
precise evidence that this has happened [98].
In the past century there have been three severe pandemics, all spread worldwide 
within a year of being detected [97]. The worse flu pandemic across Europe, Asia, 
and North America occurred in 1918-19 and was termed the “Spanish Flu” [99-102]. 
This pandemic, (H1N1 strain), is believed to have caused the death of 20 to 50 
million people worldwide [85, 99, 100, 103]. Since then, other pandemics have 
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occurred: the “Asian Flu” (H2N2) pandemic of 1957 claimed over one million lives 
worldwide after spreading from China [97]; in 1968, the “Hong Kong Flu” an H3N2 
virus was responsible for around half a million lives. HPAIV H5N1 was isolated in 
1997 for the first time from a human patient in Hong Kong [89, 95, 97]. The virus 
infected 18 patients resulting in six deaths [89, 97, 104, 105]. Recently HPAIV H7N7 
broke out in Netherlands in March 2003 and quickly spread to Belgium and Germany
[88, 89]. The virus infected 83/89 people causing conjunctivitis, and caused the death 
of one veterinarian [105]. After 1997 and 2003, other outbreak of HPAIV subtype 
H5N1 surfaced again in Vietnam’s and Thailand’s poultry industry in the early 2004 
also accompanied with human cases [94]. In 2004 in these two countries the World 
Health Organization (WHO) confirmed 46 H5N1 infections in people, of which 32
were fatal, but no cases of person to person transmission. Within a few weeks, the 
disease had spread to ten other countries in Asia, including South Korea, Japan, 
China and Indonesia [93, 106].
Although spread of AIV from birds to humans is generally rare, it has become quite 
preoccupying due to the increase in observed frequency. The probability that the 
virus could gain a form that could pass easily from humans to humans, is a possibility 
that many scientists consider, and this would have a devastating effect worldwide. 
From a total of over 385 confirmed cases of avian (H5N1) “flu” in humans, between 
2003-2008, 243 have been fatal (WHO, 19 June, 2008). Taken together, the death 
toll associated with the 1918 influenza virus correlated to the current population could 
be between 180 million and 360 million human deaths globally [107, 108]. 
1.1.5. Clinical symptoms of influenza virus infection
Influenza A and B are the major viruses responsible for the annual flu epidemics, 
which generally occur each winter. In general flu is a self-limiting disease [109], 
which does not spread further than the respiratory tract, mostly due to the 
requirement of HA cleavage for efficient virus propagation. The protease needed for 
this purpose is restricted to the lung and airway epithelium [110, 111].
The common route of “flu” transmission is by aerosol or droplets [111]. Once inhaled, 
the virus can remain in the mucus of the airways and then be transported by ciliated 
epithelial cells to the posterior pharynx. Influenza viruses cause a lytic infection of 
airway epithelial cells [112, 113].
1. Introduction
14
Typically (clinically), influenza viruses cause acute infections characterized by the 
rapid onset (about 24 – 48h after infection) of chills and fever accompanied by aches 
and pains throughout the body, malaise, sore throat, nasal congestion and 
pulmonary complications [113, 114]. Gastrointestinal symptoms have also been 
reported, particularly vomiting, abdominal pains and diarrhoea [111, 115-117]. Other 
less common symptoms include secondary bacterial pneumonia, encephalitis and 
myocarditis. Also, possible risks of complications and death are greatly increased in 
previously unexposed young children and in the elderly (> 65 years), due to their 
reduced immune function [109, 111, 116, 117].
However, once a new strain is introduced into the population, the scenario may be 
more devastating as was the case in previous pandemics and the reported H5N1 
avian strains from recent events. In these reports of highly pathogenic influenza virus 
(HPIV) infections, progressive primary viral pneumonia was generally observed, 
although secondary bacterial pneumonia was more common in the 1918 cases than 
in H5N1 infected individuals [109, 118]. Symptoms including extensive pulmonary
oedema and acute respiratory distress syndrome (ARDS), characterized by alveolar 
haemorrhage associated with massive lung infiltration of mononuclear cells are often 
lethal [109, 119]. In very severe cases, lymphopenia and multiple organ failure with 
indications of renal and cardiac dysfunction can also occur [115, 118]. There is 
limited evidence suggesting that these high pathogenic viruses replicate in non-
respiratory organs and, therefore, multiple organ failure indicates a deregulated 
immune response. Furthermore, in the 1918 pandemic there was an unusually high 
mortality rate in healthy adults ranging from 15 to 34 years, which may reflect 
immune-mediated pathology [120]. This feature has also been observed in cases of 
human infections where the avian H5N1 viruses have been highly lethal in individuals 
of all ages [111]. Another prominent and severe manifestation seen, both in the 1918 
pandemic flu and in the more recent avian H5N1 cases, was reactive 
haemophagocytosis [115, 119, 121], a disorder of the mononuclear phagocytic 
system characterized by histiocyte proliferation and extensive phagocytosis of 
erythrocytes, leucocytes, platelets and their precursors by activated macrophages
[122, 123]. This pathology profile has been associated with the multiple organ failure 
observed in very severe cases, both in the 1918 pandemic as well as in H5N1 human 
cases [109, 115, 121]. Haemophagocytic syndrome is considered to be induced by 
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increased levels of activating cytokines, with high levels of soluble (s)IL-2r, IL-6, IFN
and TNF- associated with a poor clinical prognosis [123, 124].
Furthermore, inflammation due to cytokines (i.e. TNF-, IFN/, IL-1, IL-8 and IL-6) 
has been associated with the pathogenesis of the disease. And although they are 
important components in limiting the disease, these cytokines are mainly responsible 
for the systemic symptoms observed, like fever and myalgias [114, 115, 119, 121, 
125-127].
1.2. Mechanisms of intracellular signal transduction and influenza A viruses
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Figure 1.4: Influenza A virus-activated signalling pathways. The schematic representation depicts 
intracellular signalling pathways that are activated upon IAV infection or by treatment with viral 
components. (Adapted from Ludwig et al. [128])
Many viruses are known to activate and manipulate cellular signalling pathways
[129]. These activated mechanisms lead to expression of different genes that will 
ultimately lead to viral clearance [130, 131].
Influenza A virus infection have been shown to activate different signalling pathways 
in the host cell [12, 25, 128]. Some of these cascades are depicted in Fig.1.4. 
Different pathways seem to be activated at different time points depending on 
whether it is an early or late phase of virus infection [12, 128]. PKCII activation 
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seems to be required for virus entry by endocytosis [128]. IAV leads to activation of 
all mitogen-activated protein kinase (MAPK) family members, including the 
extracellular signal-regulated protein kinases (ERKs), the p38 MAPK and the c-Jun 
NH2-terminal kinases (JNKs) [132-134]. Activation of the Raf/MEK/ERK pathway has 
been shown to be required for efficient IAV propagation [132]. p38 MAPK activation 
has been linked to expression of RANTES and IL-8, which are chemokines 
responsible for attracting eosinophils and neutrophils to the site of infection [134, 
135]. JNK has been shown to be activated upon productive replicating virus and 
induced by accumulated RNA produced by the viral polymerase [128, 133]. Activated 
JNK leads to activation of activator-protein 1 (AP-1). AP-1 includes c-Jun and ATF-2 
transcription factors which, together with nuclear factor kappa B (NF-B) and IFN 
regulatory factor (IRF)-3/-7 are important regulators of the IFN expression, one of 
the most potent antiviral cytokine, and a hallmark in virus infections [69, 128, 136]. As 
already allured to, NF-B is activated by IAV, as is the IRF-3/-7 transcription factor
[71, 137]. NF-B seems to be important to mount an antiviral state in cells, since it 
leads to expression of many pro-inflammatory and antiviral cytokines including 
IFN/. However, in studies using pre-activated NF-B or impaired NF-B signalling, 
it has been demonstrated that this pathway is also important to support virus 
replication [138, 139].
Most of these activated cascades (mentioned above) have been mainly considered 
to be events triggered by the cell as a defence mechanism (antiviral response). 
However, what seems to be evident is that influenza A virus has acquired the 
capability to evade and manipulate these responses in benefit of its own survival 
purposes, as shown for the Raf/MEK/ERK and NF-B pathways [12, 128]. 
1.2.1. The MAPK pathway (Raf/MEK/ERK signalling cascade)
Mitogen-activated protein kinase (MAPK) cascades are important signalling 
pathways that transduce many extra- and intracellular signals converting them into 
several cellular responses that lead to: growth, differentiation, development, 
inflammation and apoptosis [131, 140, 141]. They also control numerous regulatory 
processes during development and homeostasis [142-144]. More than a dozen 
MAPKs have been identified in mammals, and are organized in at least four different 
families [140, 145]. MAPKs are activated via phosphorylation by distinct upstream 
kinases on both tyrosine and threonine residues within their catalytic domains. In 
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mammalian cells, three distinct MAPK families have been well described: the 
extracellular signal-regulated kinases (ERKs), the c-Jun NH2-terminal kinases (JNKs) 
and the p38/MAPK [140, 145]. Each cascade consists of at least three enzymes that 
are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) 
and a MAP kinase (MAPK). One of the best characterized MAPK signaling pathways 
is the Raf/MEK/ERK pathway [140, 141, 145] (Figure 1.5). 
In mammals the ERK module, also known as the classical mitogen cascade, consists 
of serine/threonine kinase Raf, the S/T dual-specificity kinase MEK (Mitogen-
activated protein kinase/ERK kinase) [146] and the classical MAPK ERK 
(Extracellular-signal-regulated kinases). There are two known isoforms for both MEK 
and ERK (MEK1/2 and ERK1/2), while three isoforms, A-, B- and C-Raf (or Raf-1) 
have been identified for the Raf kinase. In their protein sequence, ERKs contain a 
Thr-Glu-Tyr (TEY) motif and become strongly activated, through phosphorylation of 
the Thr and Tyr residues [131, 141]. 
The Raf/MEK/ERK cascade is strongly activated by mitogenic stimuli, growth factors 
and cytokines and transduce signals from cell surface receptors to transcription 
factors, which regulate gene expression, which in turn can effect cell cycle 
progression, apoptosis or differentiation [147]. A schematic presentation of the 
Raf/MEK/ERK cascade is represented in Figure. 1.5.
Binding of cytokines, growth factors or mitogens to their appropriate receptors, leads 
to the activation of the coupling complex Shc/Grb2/SOS. Upon stimulation by 
Shc/Grb2/SOS, the inactive Ras exchanges GDP for GTP, leading to its 
conformational change, thereby becoming active [148, 149]. Phosphorylated 
tyrosines on receptors or on receptor substrate proteins serve as docking sites for 
SH2-domain (Src homology) of adapter protein GrB2, which binds itself via its SH3-
domain to the proline rich motif of the GDP-GTP exchange factor SOS (son of 
sevenless) [141, 150]. SOS will interact with Ras and activates the exchange of GDP 
to GTP [131, 149-151]. Ras is a small GTP-binding protein, and is the common 
upstream molecule of several signalling pathways including Raf/MEK/ERK, PI3K/Akt 
and RalGEF/Ral [148, 150, 152-154]. To date four Ras proteins have been identified 
namely Ha-Ras, N-Ras, Ki-Ras 4A and Ki-Ras 4B. Ras has to be farnysilated or 
geranylgeranylated at its carboxy-terminus to become active and therefore to be 
targeted to the cell membrane [150, 154]. GTP loaded Ras leads to recruitment of 
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the cytosolic serine/threonine kinase Raf to the cell membrane, a membrane shuttle 
kinase, and to its activation [145, 155, 156]. 
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Figure 1.5: Overview of Ras/Raf/MEK/ERK pathway. The picture shows regulation of Raf/MEK/ERK 
by Ras as wells as other kinases, which serve to phosphorylate S/T and Y resides on Raf. Some 
phosphorylation (P) events enhance Raf activity (depicted in yellow background), whereas others 
serve to inhibit Raf activity (shown with dark green background). Moreover, there are phosphatases 
like PP2a, which remove phosphates on certain regulatory residues. Activation of the PI3K/PDK/AKT 
pathway is also shown, as this pathway interacts with the Raf/MEK/ERK pathway to regulate its 
activity. PI3K can be activated by two mechanisms; either the p85 PI3K subunit can bind the activated 
IL-3Rb chain or Ras. Activated ERK can enter the nucleus and phosphorylate transcription factors. 
(Adapted from Chang et al. [148])
Raf is a serine threonine (S/T) kinase and its regulation involves a complex series of 
events involving [131, 157]: (1) recruitment to the plasma membrane mediated by 
interaction with Ras [154]; (2) dimerization/oligommerization of Raf proteins [158]; (3) 
phosphorylation/dephosphorylation on different domains [152, 159, 160]; (4) 
disassociation from the Raf kinase inhibitory protein (RKIP) and (5) association with 
scaffolding complexes that join the pathway components and ensure efficiency and 
fidelity of signal transduction [141, 148, 150]. Raf activation is mediated by multiple 
kinases like Src, PKC (protein kinase C) and Pak3 (p21 (Rac/Cdc42)-activated 
protein kinase) which lead to phosphorylation and positive regulation of Raf [131, 
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157, 161-165], whereas other kinases like PKA (protein kinase A) and Akt 
downregulate Raf activity [166, 167]. Activation of Raf can be further modulated by 
chaperonin proteins including Bag1, 14-3-3 [168] and heat shock protein 90 (Hsp90)
[169]. One of the first characterized substrate of Raf isoenzymes was the dual 
specificity kinase MEK [170].
MEKs are dual specificity-kinases that are able to phosphorylate both 
serine/threonine and tyrosine residues on MAPKs [150]. The activity of MEK1 is 
positively regulated by Raf phosphorylation on S residues in the catalytic domain
[146, 150] while activation of ERK1/2, also S/T kinases, are positively regulated by 
phosphorylation mediated by MEK1 and MEK2. Once activated, MEK transduces the
signals through phosphorylation on T-E-Y-motifs in the MAP-kinases ERK1 (p44) and 
ERK2 (p42) [150] (Figure 1.7.). ERK phosphorylation increases its catalytic activity, 
mediates oligomerisation and moderates the shuttling of the kinase to the nucleus. 
ERKs are nuclear shuttle kinases and can directly phosphorylate many transcription 
factors including Elk-1, ETS-1, c-Jun and c-Myc [171-173]. ERK can also target 
proteins e.g. serine/threonine kinases like 3pK, RNA-polymerase II, phospholipase 
A2 [173-175] and phosphorylate and activate the 90kDa ribosomal S6 kinase (p90 
RSK), which then leads to the activation of the transcription factor CREB [147, 171-
174, 176]. It has also been described that MAPK/ERK activated kinase kinase
(MEKK), through an indirect mechanism, can lead to the activation of NF-B 
transcription factor, by phosphorylating and activating inhibitor kB kinase (IKK) or/and 
IB [141, 150, 177, 178]. Expression of constitutively active components of the ERK 
pathway cause cell transformation and have been identified in several cancers [150, 
153, 175]. In support to this, activated Raf/MEK/ERK cascade has been shown to 
phosphorylate caspase 9 (an important enzyme in apoptosis induction) on residue 
T125 which contributes to the inactivation of this protein [179].
Another observation from this pathway is the fact that recent studies in an allergic 
model, have shown that the Raf/MEK/ERK is also important in controlling interleukin 
8 (IL-8) expression [180] (see also Fig. 3.4.1).
1.2.1.2. Role of Raf/MEK/ERK signalling cascade in influenza A virus infection
As mentioned before, both replication and transcription of the influenza virus genome 
takes place exclusively within the nucleus of the infected cells [181] (Figure 1.6). The 
viral RNPs will be exported from the nucleus through the cytoplasm and to the cell 
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membrane to be engulfed into budding progeny virions late in the infectious cycle [5, 
132, 181, 182]. Influenza viruses interact with many different cellular functions during 
their replication, to promote efficient propagation [12, 13, 128, 183]. Activation of the 
Raf/MEK/ERK (MAPK) signalling cascade is one of the key players for the efficiency 
of virus propagation, as already mentioned. 
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Figure 1.6: Late activation of Raf/MEK/ERK pathway in influenza A virus infection. The cartoon
depicts Raf/MEK/ERK activation during late phase of virus replication leading to vRNP export and 
efficient viral assembly at the cell surface, for budding.
This pathway is activated both early and late during the influenza virus replication 
cycle and is required for an efficient nuclear RNP export [132, 181, 182]. Analysis of 
this pathway has been facilitated by the use of highly specific MEK-inhibitors [184, 
185]. It was shown for the first time that blocking of this signalling cascade by specific 
MEK inhibitors, or using dominant negative mutants of ERK or Raf, led to impaired 
IAV as well as influenza B virus replication [132, 182]. This mechanism seemed to be 
due to retention of viral RNP in the nucleus and probably due to impaired activity of 
the viral nuclear export protein (NEP or NS2) [132, 182]. In support, studies using 
cells expressing active mutants of either Raf or MEK, virus propagation was shown to 
be increased [182]. This has also been confirmed by in vivo experiments, using 
transgenic mice expressing an active Raf in lung alveolar epithelial cells [186]. Here 
virus was shown to preferentially replicate in cells expressing the mutant gene, and 
mice survival was greatly impaired in this group [186]. What was also interesting was 
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that inhibition of this pathway with a specific MEK inhibitor, the U0126, did not 
hamper viral RNA or protein synthesis [132], showed no toxicity effect on cell viability 
or in an in vivo mouse model [132, 182, 187, 188], and did not lead to emergence of 
resistant virus variants in tests with IAV as well as influenza B virus IBV [182]. 
1.2.2. The NF-B pathway 
Transcriptional regulators of the NF-B/IB family promote the expression of over 
150 target genes, most of which play an important role in the host immune response
[128, 189-192]. These proteins include many pro-inflammatory cytokines and 
chemokines (IFN, TNF-, IL-1, IL-6, RANTES and IL-8, etc.) receptors important 
for immune recognition, proteins involved in antigen presentation, acute phase 
proteins and adhesion molecules necessary for transmigration across blood vessel 
walls. Due to this vast role in immune action, NF-B is known as the central mediator 
of the immune response [193-197]. NF-B has also been associated both with 
apoptosis and anti-apoptotic mechanisms [194, 195, 198].
The NF-B pathway seems to have been developed early in evolution and has been 
identified in Drosophila and mollusc [189, 199]. The function and also the 
components of NF-B pathway have been evolutionarily conserved in mammals
[200].
Nuclear factor-B (NF-B) proteins form a group of closely related transcription 
factors, of which there are five known members in mammals: p65 (RelA or NF-B3), 
RelB, and c-Rel (Rel), p50 (NF-kB1) and p52 (NF-kB2) [189, 191, 200, 201]. 
All five members share an N-terminal NF-B/Rel homology domain (RHD) that 
mediates DNA binding, dimerization, nuclear translocation, and interaction with the 
inhibitory IB proteins [189, 191, 200-203]. 
The NF-B, p65, RelB, and c-Rel contain C-terminal trans-activation domains (TADs) 
that trigger target gene transcription. p65 is the strongest gene activator and contains 
two potent trans-activation domains within its C terminus [189, 191, 204]. p50 and 
p52, are produced as large precursor proteins (p105 and p100, respectively), where 
p50 is generated by constitutive processing of p105, and the cleavage of p100 to p52 
is a regulated event that employs phosphorylation and ubiquitination steps [201, 
205]. The p50 or p52 homodimers are also able to repress transcription [204, 206]. 
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The most abundant and fast activated and prototypical form of NF-B is a 
heterodimer between p50 and p65 (Figure 1.7), however slow activated dimmers 
such as p52/RelB can replace the activated p50/p65 heterodimers depending on the 
promoter context [207]. NF-B is generally found retained in the cytoplasm in an 
inactive form when associated with inhibitory NF-B (IB) proteins, in most cell types
[200, 202, 208]. These inhibitory proteins share a number of protein/protein 
interaction domains called ankyrin repeats and are part of a large genetic family with 
eight known mammalian members: IB, IB, IB, IB, IBNS, Bcl-3, and the 
p100 and p105 precursor proteins [189, 200]. While IB protein caps the nuclear 
localization sequences (NLSs) of both p50 and of p65, the IB only contacts the 
NLSs of p65 [200, 209, 210]. Activated NF-B also leads to increased synthesis of 
IB which can shut down NF-B-induced gene expression by mediating nuclear 
export and dissociation of DNA-binding subunits. Therefore, in this way NF-B 
activation can be regulated by a negative feedback mechanism [189, 210, 211].
There are two general major pathways mediating NF-B activation, the so-called 
canonical (classical) and non-canonical (alternate) NF-B pathways [201, 203].
One of the critical requirements of the canonical NF-B activation pathway is the 
activation of the IB kinase (IKK) complex. All NF-B pathways converge in this step 
which ultimately leads to phosphorylation of IB at serines 32 and 36 [212-216]. 
The IKK complex is composed of three core subunits: the catalytic IKK and IKK
subunits and the noncatalytic, regulatory NEMO (NF-B essential modulator, also 
known as IKK and IKKAP-1) protein [203, 212, 213, 216, 217]. The IKK and IKK
share an N-terminal kinasse domain, and a C-terminal containing leucine zipper 
(required for IKK dimerization), and putative helix-loop-helix motifs (necessary for IKK 
regulation) [215]. It is believed that activation of both IKKs depends on their ability to 
dimerize [194, 200, 215, 216]. IKK activation depends on phosphorylation (IKK or 
IKK) at two conserved serine residues within their activation loops. This 
phosphorylation may be mediated by trans-autophosphorylation induced by 
conformational changes or by upstream-acting kinases [200, 206]. Many diverse 
stimuli can induce NF-B activation through different signalling pathways that 
converge on the IKK complex. Some of these include the: NF-B-inducible kinase 
(NIK), mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 
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(MEKK1), RNA-dependent protein kinase (PKR), protein kinase C, etc. [195, 218]. 
Also, genetic targeting experiments have shown that both IKK and IKK (NEMO), 
but not IKK, are essential for NF-B activation by pro-inflammatory stimuli, 
suggesting that both kinases have different functions [191, 206]. 
Following phosphorylation of IB by IKK, a specific ubiquitin ligase, E3RSIb, 
belonging to the SCF (Skp-1/Cul/F box) family and an E2 of the UBC4/5 family, will 
lead to its subsequent polyubiquitination [201, 219]. The ubiquitin marked IB 
proteins are then rapidly degraded by the 26S proteasome, thereby releasing NF-B
[193, 212, 219]. Activated NF-B translocates to the nucleus, where it stimulates 
transcription of genes containing the consensus sequence 5’-GGGRNNYYCC-3’, and 
transcriptional activity [189, 193, 220] (Figure 1.7). 
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Figure 1.7: Overview of NF-B pathway. The picture depicts the activation/regulation of NF-B 
pathway. Intracellular expression of viral proteins, such as HA, NP and M1 and accumulation of viral 
RNA species, indirectly via PKR, TLRs or RIG-I, can activate IKK kinase, upstream of NF-B. 
Activated IKK phosphorylates of IkBa leading to it’s ubiquitination and degradation. NF-B heterodimer 
(composed p50 and p65 subunits) is therefore released and can translocate into the nucleus and 
transactivate responsive genes. (Adapted from Ludwig, [12, 128]).
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The non-canonical pathway of NF-B activation is operative mainly in B cells in 
response to stimulation of a subset of TNF-receptor (TNFR) superfamily. Stimulation 
of these receptors activates the protein kinase NIK, which in turn activates IKK. 
Subsequently IKK phosphorylates p100 at two C-terminal serine residues, leading 
to selective degradation of its IB-like domain by the proteasome. The mature p52 
subunit and its binding partner, RelB, translocate into the nucleus to regulate gene 
expression [201, 203].
1.2.2.1. Role of NF-B signalling cascade in influenza A virus infection
NF-B can be activated by an array of different stimuli, such as inflammatory 
cytokines, mitogens, stress-inducing agents and many bacterial and viral pathogens. 
This activation is a rapid and immediate event, which occurs within minutes after 
stimulation [193, 195]. As already mentioned many of its target genes, such as 
growth factors, cytokines and their receptors, and proto-oncogenes, can influence 
dramatically the host cell cycle. Probably because of this it constitutes an attractive 
target to viral pathogens since many viruses have evolved strategies to regulate this 
pathway, such as: human immunodeficiency virus-1 (HIV-1), human T-lymphotropic 
virus-1 (HTLV-1), hepatitis B and C viruses (HBV and HCV), Epstein-Barr virus (EBV)
and influenza virus [193, 195]. In a viral context NF-B modulation can promote 
several functions: sustain viral replication, host cell survival and mediate the immune 
response to the invading pathogen. Also, since NF-B has been shown to modulate 
both pro- and anti-apoptotic mechanisms [221] some viruses have been shown to 
exploit the anti-apoptotic properties of NF-B to evade the host defence mechanisms, 
which limits replication by killing infected cells, or in contrast to induce apoptosis as a 
mechanism to increase virus spread [193].
It has been shown that influenza A virus infection results in activation of the NF-B 
pathway, either by over-expression of viral proteins such as HA, M1, and NP [222, 
223] as well as double-stranded (ds) and single-stranded (ss) RNA. The sensor 
mechanisms for this can be Toll-like receptors, such as TLR-3 -7/8, and RNA 
helicase proteins, such as RIG-I and mda-5 [224-229]. Furthermore, studies on RIG-
1 and mda-5 in influenza virus infections show a significant increase in IFN
promoter activity [230] (Figure 1.7). Nevertheless, it is important to mention here that, 
in part, the levels of NF-B activation seem to be limited by the viral NS1 protein [71].
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As mentioned before NF-B controls many antiviral and pro-inflammatory cytokines, 
and along with IRF-3/7 and AP-1, forms the important regulators of IFN, one of the 
most potent antiviral cytokines of the innate immune response. Therefore, upon 
activation one would expect an anti-viral effect of this pathway. Supporting this 
notion, in A549 cells (human alveolar epithelial cell line) infected with IAV, the 
kinetics of IFN gene expression correlated with NF-B activation [231]. Also IAV 
induction of NF-B was related to increase in expression of other pro-inflammatory 
cytokines and production of high levels of IL-8 [232, 233]. In other experiments this 
was again demonstrated, using trans-dominant negative mutants of IKK or IB  
IFN promoter activity significantly decreased upon IAV infection [71].
However, in part contradicting this theory, were studies showing that in cells with a 
pre-activated NF-B, influenza viruses showed higher replication levels [139]. And 
confirming these findings impaired NF-B signalling led to a reduction in virus titres
[71]. This function was shown to be in part due to NF-B-dependent viral expression 
of pro-apoptotic factors, such as TNF-related apoptosis inducing ligand (TRAIL) or 
FasL, which enhanced virus propagation in an autocrine and paracrine fashion [128, 
138]. Also studies using specific inhibitors of this pathway showed impaired virus 
propagation, both in vitro as well as in vivo [234]. Therefore this pathway, in the 
context of an IAV infection, presents both an antiviral as well as a pro-viral effect, 
where the pro-viral seems to prevail over the antiviral effect. One can speculate 
whether these two functions are consistent for all influenza A viruses, or whether 
either effect shows different prevalence’s, depending on which virus and at what time 
point in the infection cycle NF-B is activated by one specific strain. Nevertheless, 
most reports seem to point to this pathway being important for both, host as well as 
viral regulating mechanisms. One study, however, has shown that NF-B was not 
essential for virus replication [232]. 
1.3. Immune response and cytokine interplay
Upon influenza A virus infection, the epithelial cells of the respiratory tract and 
leukocytes which are the primary targets of the virus, will induce both innate and 
adaptive immune responses [113, 235, 236]. Respiratory epithelial cells can produce 
large amounts of virus, which can further infect alveolar macrophages (AMs) [231, 
236] (Figure 1.8). Upon infection cells will undergo either apoptosis or necrosis [113, 
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237] and trigger immune responses and the production of cytokines and chemokines
[25, 236, 238]. These inflammatory mediators have been shown to be up-regulated 
both in in vitro [238-242] as well as in in vivo experimental influenza infection [120, 
243, 244].
Mutant viruses expressing the HA and NA of the 1918 influenza virus or all 8 
segments have been shown to induce significantly higher levels of IFN, TNF-,
monocytes chemotactic protein-1 (MCP-1), RANTES, IL-6, IL-8 and up-regulated 
related genes, such as NF-B, in vivo supporting the case that elevated chemokine 
and cytokine levels were a hallmark of the human disease elicited by this virus [120, 
243, 245]. Also in vitro studies have demonstrated superior induction of pro-
inflammatory cytokines in macrophages, in particular TNF- and IFN- by H5N1 
viruses compared to other human H3N2 and H1N1 viruses [126]. In another study, 
by the same group, different H5N1 viruses (A/Hong Kong/483/97, A/Vietnam/1194/04 
and A/Vietnam/3046/04) induced higher IFN inducible protein-10 (IP-10), IFN- and 
RANTES compared to H1N1 in primary human alveolar and bronchial epithelial cells
[240]. Generally, disease severity was strongly associated with cytokine levels [114, 
115, 127]. Chemokine release, including MCP-1 and RANTES, was found increased 
in adult/neonatal macrophages infected by avian H5N1 and H9N2 compared to 
human H1N1-infected cells [244].
In a study using human alveolar epithelial A549 cells, type I IFNs were shown to be 
important for the activation of antiviral response genes, such as the MxA [231].
How influenza viruses effect hypercytokinaemia is still poorly understood, but both 
epithelial cells as well as monocytes/AMs and dendritic cells can activate different 
transcription factors upon viral infection that lead to production of pro-inflammatory 
and chemotactic cytokines, such as IFN/, IL-6, IL-8, MCP-1, RANTES, TNF- and 
others [25, 128, 227, 233, 237, 246-248].
In general the most likely in vivo situation is that upon cytokine/chemokine production 
by infected epithelial cells and/or AMs, monocytes/macrophages, neutrophils and T 
cells are induced to migrate from the blood stream through the endothelial barrier into 
the site of infection [249] (Figure 1.8). The recruitment of monocytes/macrophages 
into the lung parenchyma and alveolar spaces, is a hallmark of the initial adaptive 
immune response [237, 249, 250], and although they are required for host recovery
[251-253], an increase of their presence can lead to exaggerated inflammatory and 
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immune responses, as mentioned above, which may contribute to the exacerbation 
of the disease and the high mortality observed with some highly pathogenic influenza 
viruses, such as H5N1 and the 1918 pandemic virus H1N1 [112, 114, 115, 119, 127, 
249, 254].
Whereas the innate immune response is mainly responsible for controlling virus 
replication in the early stages of infection, the adaptive immune response is 
responsible for limiting progression of the disease. Adaptive immune responses are 
generally essential to eliminate the virus completely [235, 253, 255, 256]. The innate 
immune response is also responsible for triggering adaptive immune response 
mechanisms by secretion of cytokines which will further lead to the recruitment of 
other immune cells (macrophages, neutrophils and natural killer – NK cells) to the 
site of infection [235, 255, 257]. In turn these cells will lead to further production of 
cytokines, chemokines and other anti-viral proteins [257]. NK cells which are large 
granular lymphocytes, detect and bind to virus-infected cells [255]. Upon binding NK 
cells release the contents of their granules (containing perforins and granzymes) into 
the infected cell, thereby inducing apoptosis [115, 258].
A brief overview of some of the cytokines/chemokines and their main targets and 
functions are explained later.
As mentioned above, the innate immune response slows virus replication and 
prevents spread during the first few days of infection but survival might only be 
achieved by the “adaptive immune response” [255]. Moreover, one of the important 
features of the adaptive immune response is the “immunological memory” that is 
achieved for a specific pathogen. If an individual has been previously exposed to the 
same antigen, the adaptive immune response is much faster, due to this 
“immunological memory” [259].
Adaptive immune responses rely on the activation of antigen-specific B and T 
lymphocytes and the production of antibodies. Adaptive immune responses begin
when T cells recognise viral peptides presented in the context of major 
histocompatibility complex (MHC) on antigen presenting cells (APCs), such as 
macrophages or dendritic cells [250]. Immunological memory of B cells is lifelong but 
where influenza is concerned not very efficient since it is strain specific within an HA 
subtype, whereas T cell memory can vary from months to years or longer, but can 
distinguish between types (A or B) and not between the influenza A subtypes [253, 
260, 261].  
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Antibodies produced by B cells bind and neutralize virus on the mucosal surface to 
prevent cell entry and further replication of viruses [261].
There are two main types of T lymphocytes; T helper (Th) cells – mainly CD4+, and 
cytotoxic T lymphocytes (CTLs) – mainly CD8+. Memory Th cells can be subdivided 
into Th1 or Th2 types, and these secrete specific subset of cytokines. Th1 cells 
stimulate cell-mediated CTL immune response, whereas Th2 responses lead to 
antibody production. Th1 can best deal directly with intracellular invaders [259, 262].
CTLs recognize cells expressing surface major histocompatibility complex class I 
(MHC I)-viral peptide complexes which results in production of pro-inflammatory 
cytokines such as IFN or, like NK cells, granule-mediated killing of the target cell
[261]. These granules, containing perforins and granzymes, are transported to the 
surface of activated CTLs where contact with the target cell occurs. Granzymes are 
then transported across the cell membrane into the cytoplasm of the target cell and 
lead to induced apoptosis of the same [258, 261, 263].
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Figure 1.8: Cytokine interplay. A schematic picture showing some of the key cytokines/chemokines 
and their interplay during influenza a virus infection. The cytokines highlighted in bold blue are the key 
cytokines studied in this work. Red arrows indicate the cells the virus infects, black arrows indicate the 
secreted cytokines and green arrows indicate to which cells cytokines will exert an affect. (Adapted 
from Julkunen [25]).
H5N1 viruses have also been shown to affect specific immunity. In the presence of 
H5-bearing cells, perforin expression was suppressed and the cytoxicity of CD8+ T 
1. Introduction
29
cells reduced, and this led to lymphoproliferation, overproduction of IFN and 
macrophage activation [264, 265].
Cytokines
One of the most potent anti-viral cytokines produced by the innate immune response 
is the interferon. Interferon (IFN) was discovered as an antiviral agent during studies 
with influenza virus interference.
 IFNs can stimulate cells both in an autocrine as well as in a paracrine manner. 
In general, cells can synthesize IFN in response to an external stimulus such as viral 
infection and cells can respond to IFN by establishing an antiviral state [69, 266, 267]. 
IFNs are commonly grouped into two types [69, 262]. Type I IFNs are also known as 
viral IFNs and include IFN-, IFN-. Type II IFN is also known as immune IFN (IFN-
). Interferons (IFN-/) are one of the most important cytokines in viral infections 
and have several functions: (1) they can induce an anti-viral state to neighbouring 
cells by promoting production of anti-viral proteins; (2) they lead to recruitment of 
monocytes/macrophages and T cells (including natural killer (NK) cells); (3) they 
stimulate increase production of MHC (major histocompatibility complex) class I and 
II, which will enhance antigen presentation; and (4) increase maturation of antigen-
presenting cells (APCs), thereby leading to adaptive immune responses [266, 268, 
269].
 IFN-, type II interferon, is secreted by activated T cells (Th1 cells) and NK 
cells. IFN- can stimulate macrophages, increase antigen processing and expression 
of MHC [250, 266, 267].
 IL-1 and IL-1 are produced mainly by mononuclear and epithelial cells upon 
inflammation, injury and infection. They trigger fever, induce a wide variety of acute 
phase response (APR) genes and activate lymphocytes. 
 IL-18 is a pro-inflammatory cytokine which in synergy with IL-12, enhances NK 
cell activity and promotes inflammatory Th1 cell responses [250]. 
 IL-6 is generally produced by fibroblasts, endothelial cells, macrophages and 
leukocytes and is a primary inducer of fever, hormones, acute phase proteins and T 
and B cell expansion upon injury and infection. IL-6 can also act as an anti-
inflammatory agent in some instances. 
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 IL-12 is produced by antigen presenting cells (APCs) and has 
immunoregulatory effects on NK cells and T cells. IL-12 is important in cell-mediated 
immunity by pushing the balance between Th1 cells and Th2 cells towards Th1-type 
predominance. IL-12, in synergy with TNF-, can also elicit the production of large 
amounts of IFN- by NK cells.
 TNF- is a pro-inflammatory cytokine originally identified as a tumor cell killer, 
and mainly produced by activated macrophages, NK cells and T cells (mainly Th1 
cells). TNF- plays a role in endothelial activation and lymphocyte movement and is 
one of the crucial mediators in acute and chronic inflammatory conditions [250]. 
Chemokines 
These are small secretory molecules that are produced by a variety of cells 
constitutively or in response to microbial/viral infection [250, 270]. Chemokines bind 
to specific cell surface receptors on leukocytes, which will lead to a rapid change in 
the cell shape and behaviour enabling them to migrate from the blood stream through 
the vascular endothelium into the site of inflammation [270-272].
CC group of chemokines target many different cells, such as: monocytes, T cells, 
dendritic cells, eosinophils and NK cells. These include monocyte chemotactic 
protein (MCP)-1/CCL2, macrophage inflammatory protein (MIP)-1/CCL3, MIP-
1/CCL4, regulated upon activated normal T cell expressed and secreted 
(RANTES)/CCL5 and eotaxin/CCL11 [250, 273].
The CXC group of human chemokines mostly mediates neutrophil chemotaxis and 
include: IL-8/CXCL8, monokine-induced by IFN- (MIG)/CXCL9 (nonELR), IFN-
inducible protein-10 (IP-10)/CXCL10 and stromal cell-derived factor-1 (SDF-
1)/CXCL12. 
Lastly, the sole CX3C type chemokine, namely fractalkine/CX3CL1, binds CX3CR1 
and attracts T cells and monocytes but not neutrophils [273, 274].
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Cytokine Abbreviation Cell Source Target Cells Primary Effects
Type I Interferons 
(IFN)
IFN-
IFN- All All
Antiviral, NK cell 
cytotoxicity, induction of 
class I MHC
Type II Interferons 
(IFN)
IFN- NK cells Monocytic cells, most 
others
Activation, induction of 
class II MHC, CD4 
T-cell differentiation
Tumor necrosis 
factor (TNF)
TNF- Monocytic cells, 
NK cells, others
PMN, endothelial cells, 
hypothalamus, others
Activation of adhesion, 
inflammation, fever, cell 
death, antiviral, induction 
of class I MHC
Interleukin 1 IL-1  and  Monocytic cells, 
others
Endothelial cells, 
hypothalamus, others
Inflammation, fever
Interleukin 6 IL-6 Monocytic cells, 
others
B cells, liver Growth, acute phase 
reactants, fever
Interleukin 8 IL-8 Neutrophils and T 
cells
Chemoattractant and 
activates neutrophils
Interleukin 12 IL-12 Monocytic cells, 
dendritic cells
NK and T cells IFN- production, CD4 
T-cell differentiation
Interleukin 18 IL-18 Monocytic cells, 
few others
NK and T cells Enhances IFN- production
monocyte 
chemotactic protein 
-1
MCP-1 (CCL-2) Respiratory 
epithelium and 
monocytic cells
Monocytes, T cells and 
dendritic cells
Chemoattractant 
Regulated upon 
activation normal T 
cells expressed and 
secreted 
RANTES 
(CCL-5)
Respiratory 
epithelium and T 
cells
Monocytes, T cells and 
dendritic cells
Chemoattractant and 
activates T cells
Table 1.2: List of some important cytokines and chemokines in influenza virus infection.
Adapted from La gruta, Immunology and Cell Biology, 2007 and Biron and Sen, Innate responses to 
viral infections Chp 9, Fields Virology, 5th edition.
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Figure 1.9: The two cellular pathways targeted in this study (NF-B) and (Raf/MEK/ERK). The 
cartoon shows the activation of the two pathways by IAV particles, and the specific targets of the 
inhibitors used in this study; the IKK inhibitor (Bay 11-7082) for the NF-B pathway and a MEK 
inhibitor (U0126) for the Raf/MEK/ERK pathway. Both pathways are required for (1) efficient virus 
propagation, by means of vRNP export from the nucleus, as well as (2) antiviral functions, by means of 
cytokine/chemokine expression, upon virus infection. (Adapted from Pleschka).
Influenza A viruses are segmented ssRNA viruses which mainly target the epithelial 
cells of the respiratory tract in humans and generally cause acute, self-limiting 
infections [1, 25, 109]. Possible risks of complications and death are, however, 
greatly increased in young children, the elderly [109, 111, 116, 117] or when the 
population comes into contact with new highly virulent virus strains [76, 109, 126]. 
Increase virulence and high viral loads as well as severe lung inflammation due to 
cytokines (i.e. TNF-, IFN/, IL-1, IL-8, MCP-1 and IL-6), has been linked with the 
pathogenesis of these HPIV strains. The associated hypercytokinaemia is thought to 
be responsible for the main systemic symptoms observed and the severity of the 
disease [114, 115, 119, 121, 125-127].
Therapeutics strategies in the form of antiviral drugs such as amantadine and 
rimantadine, which target the viral M2 ion channel protein as well as neuraminidase 
inhibitors, zanamivir and oseltamivir, can reduce the duration of symptoms of clinical 
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influenza, but the appearance of drug-resistant variants have already been reported 
[12, 106, 275-278]. Vaccination is also an option, but in the possible appearance of a 
pandemic situation, the appropriate vaccines would not be produced in time [279, 
280] to avoid disaster. Therefore the need for new therapeutic strategies is urgent.
Upon IAV infection cells activate many signalling pathways such as; the 
Raf/MEK/ERK, the NF-B, the p38 MAPK, the JNK, the IRF-3 and PI3K pathways. 
[12, 13, 183, 281].
Activation of the NF-B transcription factor has been shown to be important for the 
expression of many pro-inflammatory and antiviral cytokines (anti-viral function) [232, 
233] as well as important in supporting virus replication (pro-viral function) [138, 139, 
234]. The Raf/MEK/ERK (MAPK) signalling cascade, on the other hand, has 
generally been linked to efficient influenza virus propagation [132, 182, 282]. This 
pathway has, however, in other studies also been shown to be involved in cytokine 
regulation [135, 283].
Specific inhibitors that block activation of the NF-B pathway, such as Bay 11-7082 
(Bay) by selectively inhibiting TNF- inducible phosphorylation of IB
(www.calbiochem.com), or U0126 a MEK inhibitor [284] which inhibits downstream 
activation of the Raf/MEK/ERK pathway, have already been previously used in 
studies with influenza virus [132, 139, 181, 182].
The aim of this study was to modulate both virus replication as well as virus-induced 
cytokine production simultaneously, by targeting these two pathways (NF-B and 
Raf/MEK/ERK) using the specific inhibitors mentioned above (Figure 1.9). This idea 
envisioned targeting these specific cellular pathways shown to be important for virus 
replication and for virus-induced cytokine expression with the purpose of limiting the 
main factors linked to the severe disease outcome of infection with certain HPIV 
strains.
The aim also included comparison/correlation studies in cell culture experiments 
using either permanent cell lines (human alveolar epithelial cells – A549 cells) or 
primary cells (mice alveolar epithelial cells – AECs), as well as in vivo studies using 
C57BL/6 mice.
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2. Materials and Methods
2.1. Materials
2.1.1. Instruments
Abbocath-T (26Gx19mm) Hospira
Bio Imaging Analyzer (BAS 2000) Fuji Film
Cell culture incubator Heraeus; Nuaire
Cell culture microscope Hund
Confocal laser scanning microscopy (TCS SP5) Leica
Culture Hood(HB2448) Heraeus
Developing machine Optimax, Protec
Disposable Razor Med Comfort AMPri GmbH
Electrophoresis apparatus system Institute for Medical Virology
Electrophoresis power supply (EPS500/400) Pharmacia
ELISA reader (Type LP 400) Diagnostic Pasteur
FACScan Becton Dickinson, USA
Fine scale (Mettler PM460) Mettler Waagen GmbH
Heat block Jumotron
LuminexTM Reader Biorad
Magnetic stirrer IKA Labortechnik
Megafuge 1.0 R Heraeus
Microwave oven Quelle
Mini centrifuge Biofuge 13, Heraeus
Neubauer chamber Optik Labor
Omincan 50 Braun Medical
pH meter (Type 632) Metrohm
Shaker (Type 3013) MSGV GmbH
Scale (P1200) Mettler
Scanner Canonscan 9900F Canon
SDS-PAGE gel system Institute for Medical Virology
Sonicator (Type HD70) Bondelin Sonoplus
Spectrophotometer (DU-70) Beckman
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Sterile needles BD Microlance 3 BD 
Syringe (microliter, serial 700) Hamilton
Syringe 20ml single use Braun, Melsungen AG
Tissue Ruptor Qiagen
Vortex(Vibrofix VF1) IKA Labortechnik
Water bath (SW-20C) Julabo
Western-Blot chamber Institute for Medical Virology
2.1.2. Reagents and general materials
Acrylamide Bio-Rad
Ammonium persulfate (APS) Serva
Annexin V-FLUOS Roche
Aprotinin Roth
β-mercaptoethanol (MetOH) Roth
Benzamidin Sigma
Blotting papers (GB004) Scheicher & Schuell
Bradford reagent Biorad
Bromophenol blue Merck
BSA (Solution, 35%) MP Biomedicals
BSA (Powder) Roth
Chloroform Roth
Coomassie brilliant blue R 250 Merck
Cryotubes Nunc
DAB Peroxidase substrate 
(3,3’-Diaminobenzidine)
Sigma
DAPI (stock 1mg/ml) Roth
DEAE Dextran (MW: 500,000) Pharmacia Biotech
1,4-Diazabicyclo 2,2,2octane (DABCO) Merck
Dimethylsulfoxid (DMSO) Sigma
1,4-Dithiothreit (C4H10O2S2) (DTT) Roth
Cuvette Biorad
Eppendorf tube Eppendorf
Ethanol (absolute) Roth
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Ethylenediamine tetraacetic acid (EDTA) Fluka
Falcon centrifuge tube Falcon
Glycerol Sigma
Glycine Roth
Hydrochloride (HCl) Roth
Isopropanol Roth
Leupeptin Sigma
Magnesium chloride (MgCl2) Merck
Methylcellulose (methocel MC) Sigma
Microtiter plate (96 wells) Greiner
Mowiol 40 - 88 Aldrich
Methanol Roth
MTT (dimethylthiazole-diphenyl tetrazolium 
bromide)
Sigma
N-2-hydroxyethylpiperazine (HEPES) Sigma
Paraformaldehyde (PFA) Merck
Pefablock Roth
Potassium chloride (KCl) Roth
Precision Plus Protein Standards (All Blue) BioRad
Potassium dihydrogen phosphate (KH2PO4) Roth
Propidium Iodide Sigma
PVDF-Membrane Immobilon-P transfer membrane Millipore
Rainbow marker Amersham
Roti-Free, ready-to-use Stripping Buffer Roth
Scientific Imaging film BioMax MR Kodak
Sodium chloride (NaCl) Roth
Sodium dodecyl sulfate (SDS) Merck
Sodium-β-glycerophosphate Sigma
Sodium hydroxide (NaOH) Merck
Sodium hydrogen carbonate (NaHCO3) Fluka
Sodium orthovanadate Sigma
Sodium pyrophosphate Sigma
TEMED (N,N,N',N'-Tetramethyl-ethylene diamine) Serva
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Tris HCl Roth
Triton X-100 (t-Octylphenoxypolyethoxyethanol) Sigma
Tween 20 Roth
Trypan blue Gibco
Whatman 3MM Papier Schleicher & Schüll
WST-1 Cell proliferation Reagent Roche
2.1.3. Monoclonal and polyclonal antibodies
Antibody Company Dilution
Anti-P-ERK (E-4) mouse monoclonal IgG Santa Cruz 
Biotechnology
1:250
Anti-ERK2 (C-14) mouse monoclonal IgG Santa Cruz 
Biotechnology
1:500
HRP conjugated goat anti-mouse IgG Santa Cruz 
Biotechnology
1:1000
Anti-flu A NP (FPV) mouse (clone 1331) Biozol–Biodesign 
Internat.
1:6000
Anti-influenza A PR/8/34 chicken polyclonal 
IgY
Biomol – US Biological 1:50
Texas Red conjugated rabbit anti-mouse Dianova 1:200
biotinylated rat anti-mouse CD16/32 BD Pharmingen 1:?
biotinylated rat anti-mouse CD45 mAbs BD Pharmingen
2.1.4. Materials for cell culture
Dulbecco's Modified Eagle's medium (DMEM) Invitrogen/Gibco
Fetal calf serum (FCS) PAN
penicillin-streptomycin solution (100x) PAA
Trypsin-EDTA (10x) PAA
Tissue culture dish Becton Dickinson
Tissue culture flask NUNC
Bovine Albumin ICN
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2.1.5. Materials for mice experiments
Agarose low melting Sigma Aldrich
Dispase BD Biosciences
DNase Serva
HBSS PAA
Isofluorane Abbott/Baxter
MagneSphere Paramagnetic Particles Promega
Syringe (microliter, serial 700) Hamilton
Mesh filter membrane 100M and 40M Beckton Dickinson
Filter paper 20M Milipore
2.1.6. Kits
AEC staining kit Sigma
Anti-mouse IFN ELISA kit BioSource/Invitrogen
Anti-human IFN ELISA kit BioSource/Invitrogen
ECL (enhanced chemiluminescence) solution kit Amersham/GE
Multiplex human cytokine kit BioRad
Multiplex mouse cytokine kit BioSource/Invitrogen
NF-B TransAM ELISA kit AtiveMotiv
Opteia set mouse TNF- kit BD Biosciences
2.1.7. Virus strains and cell lines
A/FPV/Bratislava/79 (H7N7) Strain-collection in Giessen
A/PR/8/34 (H1N1) Strain-collection in Giessen
A549 (Human Alveoar Epithelial cells) Strain-collection in Giessen
MDCK-S  (Madin-Darby canine kidney cells) Strain-collection in Giessen
Vero (African Green Monkey) Strain-collection in Giessen
2.1.8. Inhibitors and solvent
Bay 11-7082 (IKK inhibitor) Calbiochem
U0126 (MEK inhibitor) Promega
Cremophor EL Fluka
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2.1.9. Media
Dulbecco s´ Modified Eagle Medium (DMEM 10L)
1x DMEM powder high glucose
37 g/10 L bicarbonate
100 ml/10 L sodium pyruvate
100 ml/10 L 100x penicillin/streptomycin
sterile filtered
Freeze medium
90% Complete DMEM
10% DMSO
DMEM/10% FCS/antibiotics (complete DMEM 0,5L)
445 ml DMEM
50 ml FCS (heat inactivated)
5 ml 100x penicillin/streptomycin
DMEM/BA (0,5L)
492 ml DMEM
5 ml penicillin/streptomycin (100x)
3 ml Bovine Albumin (BA) (35%)
2x DMEM/BA for Plaque-Assay (0,5L)
100 ml  MEM (10x)
10 ml  penicillin/Streptomycin (100x)
20 ml NaHCO3 (7.5%)
6 ml Bovine Albumin (BA) (35%)
354 ml ddH2O, autoclaved
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2.1.10. Buffers and solutions
100x Ca2+/Mg2+ solution (100ml)
1 g MgCl2
1.32 g CaCl2
ddH2O added up to 100 ml
autoclaved, then filtered with the 0.2µm filter column
Phosphate-Buffered Saline (10x PBS) (1L)
0,137 M NaCl
0,27 mM KCl
8,1 mM Na2HPO4
1,47 mM KH2PO4
adjust total volume to 1 L with ddH2O, autoclaved
1x PBS++ buffer (0,5L)
495 ml 1x PBS (autoclaved)
5 ml Ca2+/Mg2+ solution (100x)
PBS/Ca2+/Mg2+/BA/antibiotic (200ml)
20 ml 10x PBS (see above)
174,8 ml ddH2O (sterile)
2 ml  penicillin/streptomycin (100x)
1,2 ml BSA (35%)
2 ml  Ca2+/Mg2+ (100x)
SDS-PAGE loading buffer (2x) (Laemmli Buffer)
100 mM Tris-HCl, pH 6.8
200 mM DTT (dithiothreitol)
4% SDS
20% glycerol
0.2% bromophenol blue
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SDS-PAGE running buffer (5x) (1L)
1 g SDS
6 g Tris HCl
28,8 g glycin
adjust total volume to 1 L with ddH2O
SDS-PAGE transfer buffer (1L)
5,8 g Tris HCl
2.9 g glycin
0.17 g SDS
200 ml methanol
adjust total volume to 1 L with ddH2O
TLB buffer
20 mM Tris HCl, pH 7.4
137 mM NaCl
10% (v/v) glycerol
1% (v/v) Triton X-100
2 mM EDTA
50 mM sodium-β-glycerophosphate
20 mM sodiumpyrophosphate
(Addition of inhibitors for lysis buffer, see below)
Lysis buffer (10ml)
10 ml TLB buffer (see TLB buffer)
10l Pefablock (200 mM)
10l Aprotinin (5 mg/ml)
10l Leupeptin (5 mg/ml)
100l Sodium orthovanadate (100 mM)
50l Benzamidine (1 M)
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Tris-Buffered Saline (10x TBS) (1L)
24.2 g Tris HCl
80 g NaCl
dissolve by adding 900 ml ddH2O
adjust pH to 7.6 and total volume to 1 L with 
ddH2O
TBS/Tween (0.05%) (1x TBS-T) (1L)
100 ml 10x TBS
900 ml ddH2O
0.5 ml Tween 20 
Blocking buffer and antibody diluting solution
5% (w/v) nonfat dry milk
in 1x TBS-T (see above)
2.1.11. Gels and other media
SDS-PAGE stacking gel
2,9 ml ddH2O
1,25 ml Tris HCl, pH 6.8 (0.5 M)
50 l SDS (10%)
750 l polyacrylamide (PAA) (30%)
50 l  APS (10%)
4 l TEMED
SDS-PAGE resolving gel (10%)
4 ml ddH2O
2,5 ml Tris HCl, pH 8.8 (1.5 M)
100 l SDS (10%)
3,3 ml polyacrylamide (PAA) (30%)
50 l APS (10%)
6 l TEMED
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Cell fixing buffer (100 ml)
95 ml PBS++
4 ml Formaldehyde (PFA)
1 ml Triton X-100 (t-Octylphenoxypolyethoxyethanol)
Methyl cellulose stock, 3% stock for Focus assay (200ml)
6 g methylcellulose
200 ml ddH2O 
heat ddH2O up to 90°C
add methylcellulose by using a sieve, mix thoroughly and autoclave
ripen it at 4°C for three days
aliquot in 50 ml and freeze at -20°C
Methyl cellulose media, 1.5% stock (100 ml) for Focus assay
50 ml methyl cellulose stock (3%)
1 ml Penicillin/Strepromycin (100x)
1 ml BA (30%)
10 ml MEM (10x)
4 ml NaHCO3 (7.5%)
1 ml DEAE Dextran (MW: 500,000) (1%)
33 ml ddH2O
mix well and store at 4°C
Mowiol DABCO
2.4 g Mowiol
6 g Glycerol
6 ml ddH2O
mixed thoroughly over night. Next day add 12 ml 0.2 M Tris-HCl (pH 8.5) and 
incubated at 50°C for 30 min. Centrifuge the viscous mixture at 12000 g (Megafuge 
1.0R, 6000 rpm) at room temperature for 15 min, and mix the supernatant with 2.5% 
DABCO.
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U0126 and Bay 11-7082 stock
U0126 M [380,5g/L] and Bay 11-7082 [207.2g/L]
Both inhibitors were prepared to a stock concentration of 100mM dissolved in DMSO. 
Aliquots were then made and stored at -20oC.
Cremophor EL [(Polyoxyethylenglyceroltriricinoleat 35 (DAC), Polyoxyl 35 Castor Oil 
(USP/NF) is a trademark of BASF, Germany] is a non-ionic solubilizer and 
emulsifier. It can convert hydrophobic drugs into aqueous solutions. Addition of 
Cremophor EL to a drug, allows for fine degree of dispersion and therefore the drug 
is more readily absorbed and its efficiency is increased.
For the dissolving U0126, we first used DMSO and then further added Cremophor EL 
in a ratio of 1:4. The above solution was then further diluted in filtered PBS (total 
volume 250l/mouse) for in vivo application.
2.2. Methods 
2.2.1. Working with cell cultures
2.2.1.1. Maintenance of cell culture
Mardin-Darby canine kidney cells (MDCK) and human Alveolar epithelial carcinoma 
cells (A549)  were maintained in Dulbecco modified Eagles medium (DMEM) 
containing phenol red as a pH-indicator, supplemented with 10% heat inactivated 
fetal calf serum (FCS) and streptomycin/penicillin. The cells were incubated at 37°C 
with 5% CO2 and 95% humidity. They were routinely cultured to 100% confluence 
and than passaged according to the needs.
2.2.1.2. Storage of cell cultures
For freezing; cells were washed with 1x PBS and 5 ml of 1x trypsin-EDTA was then 
added. They were then incubated at 37°C with 5% CO2 and 95% humidity and left 
until cell detachment, after which 5ml complete media was added. Cell suspensions 
were then centrifuged at 350 g (Megafuge 1.0R, 1000 rpm), 4°C for 5 min. The cell 
pellet was gently resuspended with 1 ml freeze medium (90% complete DMEM and 
10% DMSO) and transferred into cryotubes. These were set into a styropore box and 
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left to freeze gradually in the -80°C freezer. The DMSO prevents ice crystal formation 
and allows the cells to remain intact. After 24 hours, cells were transferred into liquid 
nitrogen where they can be kept for a longer period of time.
For thawing; cells were removed from liquid nitrogen and immediately transferred 
into a 37°C water bath for 5 min. Cells were then resuspended carefully and 
transferred into a cell culture flask filled with complete DMEM (19 ml). After 24h cells 
will have reached 100% confluency and should be passaged for further propagation.
2.2.1.3. Infection of cells
Influenza virus, avian A/FPV/Bratislava/79 (H7N7) and human A/PR/8/34 (H1N1), 
were used for infection of A549 cells. The virus inoculum was prepared by adding the 
according amount of virus stock to a certain volume of PBS/BA/P/S/Ca2+Mg2+
depending on the desired multiplicity of infection (moi) used for experiment. A549 
cells were previously (one day before) seeded on 3.5 cm dishes and grown to 
confluence. The cells were then washed with 1x PBS++ and 100 µl of virus inoculum 
was laid on top by creating bubbles in the middle of dish, to ensure a consistent virus 
distribution. The cells were further incubated at room temperature for 1 hour, after 
which the inoculum was removed by aspiration and 2 ml of DMEM/BA media was 
added with the desired treatment (DMSO, Bay 11-7082 or U0126) or untreated. Cells 
were then further incubated at 37°C with 5% CO2 for the desired time points, and 
further treated. 
The calculation of moi was done as follows:
2.2.2. Preparation of cell lysates for Western blot analysis
At a certain time point after infection and/or treatment, cells (from 3.5cm dishes) were 
washed with cold 1x PBS++. An extra 1 ml of cold 1x PBS++ was added to the cells 
with which they were scraped off and transferred into eppendorf cups. This was then 
centrifuged at 25000 g (Biofuge 13, 13000 rpm) for 1 min and the cell pellet carefully 
resuspended in 75 l lysis buffer by pipetting up and down. The lysis was performed 
by incubating cells for 25-30 min on ice and vortexing at every 5 min intervals. The 
1000 µl
Virus titer [PFU] moi x cell amount in the culture
X µl virus
=
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lysed cells were then centrifuged at 25000 g (Biofuge 13, 13000 rpm), 4°C for 15 
min. The supernatant was finally transferred into new eppendorf cup and stored at -
70°C until further requirement.
2.2.3. Cell viability (cytotoxicity) analysis
In order to determine whether the concentration of inhibitors used for experiments 
would affect cell viability, MTT-assay or WST-1-ssay was performed. Both these 
assays measure the activity of mitochondrial dehydrogenase in the living cells. 3-
(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) or (4-(3-(-
iodophenyl)-2-(4-nitrophenyl)-2H-5tetrazolio)-1,3-benzene disulfoonate) (WST-1) is 
taken up by cells and can be reduced either enzymatically (by mitochondrial 
dehydrogenase/reductase enzymes) or through direct interaction with NADH, which 
is reduced to NADPH. This reaction only takes place when enzymes are active in 
living cells and therefore conversion is directly related to number of viable cells and 
can be analyzed photometrically in an enzyme-linked immunosorbent assay (ELISA) 
reader. 
This reaction produces blue formazan crystals (MTT) or yellow formazan (WST-1) in 
living cells.
2.2.3.1. MTT-assay
A549 cells were seeded in 96well cell culture plates (150l/well) and grown in 
complete DMEM media overnight at 37°C with 5% CO2 so that they were confluent 
on the day of the experiment. After addition of the inhibitors (mixed in DMEM/BA), 
cells were incubated further for 4, 6, 8, 10, 24 and 48 hours. Cell media was then 
replaced with 150l of complete DMEM media and incubated for 1 hour to allow for 
cell proliferation. 7l of 5mg/ml MTT stock solution was diluted in 193l complete 
DMEM media (175g/ml final concentration) and added into each well after aspirating 
the old media. Cells were incubated for a further 90 min and subsequently fixed with 
4% paraformaldehyde (PFA, in 1x PBS) at room temperature for 30 min. The fixing 
solution was aspirated and the plates were dried under the hood for 10-15 min. The 
tetrazolium crystal was dissolved by adding 200l of isopropanol to each well and the 
plates left shaking for 10 min on a 96-well plate shaker. The plates were analyzed 
photometrically at 550 nm excitation in an enzyme-linked immunosorbent assay 
(ELISA) reader.
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2.2.3.2. WST-1-assay
This assay can be performed in living cells, without any need of fixing the cells.
The media was always prepared fresh (for 24 well plates – 300l/well), by diluting 
1:50 of WST-1 stock in DMEM without phenolred.
The supernatants were collected from the treated cells/samples and kept at RT for 
the duration of the WST-1 experiment (it was later added back to the cells).
The cells were washed once with PBS, after which 300l of the 1:50 prepared 
solution (see above) was added per well. The cells were then incubated for 1h at 
37°C and 5% CO2 (for A549 cells) or 7.5% CO2 (for mice primary cell culture). After 
the elapsed time 100l of supernatant was removed and placed in duplicate into a 
96-well ELISA plate. The absorbance was measured at 450nm – reference set to 
620nm – in an enzyme-linked immunosorbent assay (ELISA) reader.
Absorbance results from time point post-treatment (viral infection and/or +/-
inhibitors) and for each individual well were then correlated to initial results before 
treatment (time point zero) and given as percentage values. 
2.2.3.3. Trypan Blue dye exclusion
For the exclusion of dead cells, 10ml of cell suspension (in media) was added to 
90ml of Trypan blue. It was mixed gently up and down with a pipette and 10ml of this 
dilution was placed in a Neubauer chamber and counted. Trypan blue enters and 
stains dead cells are whereas the unstained cells are live. 
The cell number (dead/alive) was counted taking into account the dilution factor (10) 
from above and the Neubauer chamber multiplication factor 1000.
2.2.4. Raising virus stocks
T-75 flasks were seeded with MDCK-S or Vero cells one day before and allowed to 
grow to +/- 90% confluency. A preparation of the virus stock was made to infect 
bottles at a moi=0.01. The bottles were washed with 5ml PBS++ and then infected 
with 5ml of virus stock in PBS/BA/P/S/Ca2+Mg2+ for 1hour at RT. After this incubation, 
the inoculum was removed and 10ml of DMEM/BA media was added to the bottles 
and incubated at 37°C and 5% CO2 for approximately 48h or until liquid plaques were 
seen. In the case of A/PR/8/34 virus, Trypsin at 2g/ml was additionally added to the 
media for cleavage of the HA, which is necessary for efficient replication. 
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Supernatant was then removed, centrifuged at 350 g (Megafuge 1.0R, 1100 rpm), 
4°C for 5-10 min, and the clear supernatants collected from the tubes. The analysis 
of titres and HA were then calculated, as described below.
2.2.5. Analysis of infectious virus titres by immunohistochemistry
Virus dilution was prepared in a 96-well microtiter plate with U-form bottom. First 
180l of PBS/BA/P/S/Ca2+Mg2+ was pipetted into each well and 20 l of the virus 
stock was added into the well of the first row. The virus dilution (200 l) was mixed by 
pipetting up and down and 20 l of it was transferred into the well of the second row. 
The same steps were repeated up to the last row to get 10-1 to 10-8 dilution series.
MDCK cells were seeded in 96-well plates and grown over night at 37°C with 5% 
CO2 so that they were 90% confluent on the day of infection. The cells were washed 
once with 1x PBS++, then infected with 50l of virus dilution and incubated at room 
temperature for 1 hour. Virus inoculum was aspirated and 150l methylcellulose 
media was added into each well. In the case of A/PR/8/34 virus titration, Trypsin at 
2g/ml was additionally added to the methylcellulose media for the reason stated 
above (section 2.2.4.). The plate was placed at 37°C with 5% CO2 for 30 or 48 hours, 
for FPV or PR8, respectively. After time of incubation, methylcellulose media was 
removed by aspiration. Cells were washed twice with 1x PBS++ and fixed, as well as 
permeabilized, with 100l/well of 4% PFA/1% TritonX-100 in 1x PBS++ overnight at 
4°C or alternatively for 1 hour at RT. Afterwards cells were washed three times with 
1x PBS/0.05% Tween20 and incubated with 50 l of primary antibody (anti NP-mAb, 
1:6000 diluted in PBS++/3% BSA) for 45 min at room temperature. After aspirating the 
primary antibody dilution, cells were again washed three times with PBS/0.05% 
Tween20, followed by secondary antibody  incubation (Horse Radish Peroxidase 
(HRP)-conjugated anti mouse, 1:1000 diluted in PBS++/3% BSA) for 45 min at room 
temperature. Cells were washed as before and 100l DAB-substrate (first, one silver 
pill (Sigma FASTTM DAB) dissolved in 15 ml 1x PBS followed by dissolving one 
golden pill (Sigma FASTTM UREA H2O2)) or 50l of AEC staining kit solution was 
used and was added into each well and placed at room temperature for 10-15 min.
The AEC (3-Amino-9-ethylcarbazole) Staining Kit is used for staining peroxidase 
labelled compounds in immunohistochemistry or immunoblotting techniques. AEC 
produces an insoluble end product which has a red colour. Brown or red stained foci
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were observed under microscope, wells were washed with normal water to remove 
the rest of salts and air dried at room temperature. After drying, the plates were 
scanned using the Canonscan 9900F at 1600 dpi and virus foci counted. The viral 
titre was determined as follows:
FFU/ml = number of foci x volume factor x dilution factor
Volume factor: FFU (Foci forming unit) is related to 1 ml. If a dish was infected with 
50 l viral dilution solution, the factor is 20. 
One foci was considered when more than 3-5 adjacent cells were stained in one 
particular area, as opposed to single cell staining which would probably mean, that 
the cell had not produced an infectious virus.
2.2.6. Haemagglutination (HA) Assay
2.2.6.1. Preparation of red blood cells (RBCs) from chicken blood
Red blood cells should be taken from Specific Pathogen Free (SPF) chickens. If SPF 
chickens are not available, blood may be taken from normal chickens that are shown 
to be free from antibodies to avian influenza. First, about 20-30 ml fresh chicken 
blood was transferred to a 50 ml sterile Falcon centrifugation tube containing 10 ml of 
3.7% sodium citric acid. The RBCs were washed by filling the tube to 50 ml with PBS 
and centrifuged at 700 g (Megafuge 1.0R, 1100 rpm) at 4oC for 10 min. The 
supernatant above the RBC-fraction containing serum, white blood cells and fat was 
carefully removed by aspiration, then RBCs pellet was washed again with PBS and 
centrifuged as mentioned above. This washing step was repeated twice. Finally the 
pellet of RBCs was diluted to 0.5% (v/v) with PBS for haemagglutination assay.
2.2.6.2. HA assay
50 l PBS was distributed into each well of a plastic U- or V-bottomed 96-well plate. 
50 l of virus suspension (from cell culture supernatant) was placed in the first well 
and two-fold dilutions performed from well to well (left to right) in a row (12 wells), so 
that the final dilution on well no.12 was 1:4096. Subsequently 50 l of 0.5% chicken 
RBCs was added to each well and the plate gently tapped to allow for even mixing. 
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The RBCs were then allowed to settle for about 30-60 min at 4oC. The 
Haemagglutinating Units (HAU) are measured as: 2x, where X is the number of the 
last well without blood precipitated on the bottom (with a mesh of erythrocytes). 
2.2.6.3. HI assay
25 l PBS was distributed into each well of a plastic U- or V-bottomed 96-well plate. 
In the first well, 50 l of antibody dilution (Chicken anti-influenza A, Puerto Rico 8/34 
(H1N1) Pab – IgY) (1:50) (dilution previously tested) was added and then a 2-fold 
dilution was performed (25l from first well to second, etc…) until well no.12 and 
discarded 25l from this last well. To each well 25l of virus dilution was added 
(previously tested for HA – 3 wells below the last positive well dilution) (i.e. if HA=26; 
then dilute the virus to 24 = 1/16 = 100l + 1500l PBS/BA/P/S/Ca2+Mg2+) and 
incubated for 30min-1h at RT.
After the incubation 50 l of chicken erythrocytes were distributed to each well; only 
pipetted on top and not shaken. The plate was then left at 4oC for 45min-1h. 
Haemagglutination inhibition was visualized, in contrast to HA, by the wells that had 
RBC precipitated at the bottom. 
2.2.7. Confocal Laser Scanning Microscopy and Immunofluorescence Assay 
(IFA)
Confluent cells were trypsinized by 1x trypsin-EDTA, reseeded in the 3.5 cm dish 
containing sterile glass cover-slips (12 mm) and incubated at 37°C with 5% CO2. On 
the next day, the cells were confluent. After infection and treatment of cells, the 
growth medium was removed from the culture dish, and the cells were washed once 
with 1x PBS++, then the cells were fixed with 1 ml 4%PFA in 1x PBS++ over night at 
4°C. After fixation, cells were washed twice with 1x PBS++ and subsequently 
incubated with 1ml 1% Triton X-100 for 45 min. Cells were then washed 3 x with PBS 
and incubated with 20 l of the primary Anti-flu A NP (FPV) mouse (clone 1331) 
(1:200 dilution in PBS++/3% BSA) for each cover-slip for 1 hour at room temperature. 
Afterwards cells were washed three times as before, and further incubated with 20 l 
of the secondary TexasRed-labeled goat anti-mouse IgG (1:200 diluted in PBS++/3% 
BSA) for 1 hour at room temperature. The cells were then washed again three times 
and incubated with 20l DAPI stock (1:200 diluted in PBS++/3% BSA) for 5 minutes. 
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After a further three washes (as above) and an extra wash with ddH2O, the glass 
cover slip was fixed on a glass slide with Mowiol, and allowed to harden overnight. 
Fluorescence was visualized, and pictures taken the following day with a TCS NT 
confocal laser scanning microscope.
2.2.8. Western blotting (Semi-dry)
2.2.8.1. Measurement of relative protein concentration (Bio-Rad protein assay)
The Bio-Rad Protein Assay is based on the observation that the absorbency 
maximum for Coomasie Brilliant Blue G250 shifts from 450 nm to 595 nm when 
binding to protein [285]. 5 l of cell lysate (as described in section 2.2.2.) was added 
into diluted Bio-Rad Dye Reagent (1:5 dilution of Dye Reagent concentrate in 
ddH2O). This was then mixed well and after a period of 10 min, the protein content 
was determined by measuring the absorption at wavelength 595 versus reagent 
blank (containing the lysis buffer only). This was done to apply an equal amount of 
protein from all samples onto the SDS-PAGE gel. The calculation was done as 
follows: the OD value (ODref) of the sample with lowest concentration (Reference 
sample Cref) was divided by the OD values (ODx) from the other samples. This would 
give a factor value (Fx) that would be multiplied by a constant volume (i.e. 70l). The 
respective volume obtained (Vx – representative of the volume needed from each 
individual sample) would then be subtracted from the respective 70l and this would 
give the amount of lysis buffer volume (Lx) that would be needed to add to the Vx to 
obtain the same amount of protein concentration from the lowest sample 
concentration.
2.2.8.2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
The eletrophoresis apparatus was assembled according to manufacturer's (Bio-Rad) 
instruction, and the resolving gel was poured in between the two glass plates. A 
space of about 1 cm plus the length of the teeth of the comb was left uncovered. 
Isopropanol or 100% ethanol was added to the surface of the gel to apply achieve an 
even gel surface. After the resolving gel was polymerized, isopropanol was removed 
and the stacking gel was poured on top of the resolving gel. The comb was then 
inserted on the top and the gel and allowed to polymerise. 35 l of 2x Laemmli buffer, 
containing 10% β-mercaptoethanol to reduce disulphide bonds, was added to 70 l of 
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sample (after determining the protein concentration) and was incubated for 5 min at 
95oC and cooled on ice for 1 min, then shortly centrifuged and then 25l of the 
adjusted protein concentration (see section 2.2.8.1.) was loaded into the wells of the 
gel. Rainbow protein marker or Precision Plus protein standard (2 l marker + 8 l 
Laemmli buffer) was loaded as control. Electrophoresys buffer was added and the 
gels were run at about 20 V/cm gel length. The negatively charged SDS-proteins 
complexes will migrate in the direction of the anode at the bottom of the gel. Small 
proteins move rapidly through the gel to the bottom, whereas large ones move slower 
and stay on the top. Proteins that differ in mass by about 2% can be distinguished 
with this method. The electrophoretic mobility of many proteins in SDS-
polyacrylamide gels is proportional to the logarithm of their mass.
2.2.8.3. Transfer to membrane in a "Semi-dry" electroblotter 
After the cell extracts were subjected to SDS-PAGE, the proteins were transferred 
onto a PVDF-membrane by electroblotting. The membrane had been previously 
incubated in 100% methanol for 1-2 min, washed for 5 min in ddH2O, and further 
equilibrated for 5 min in transfer buffer. A sandwich of two blotting papers, the PVDF-
Membrane, the polyacrylamide gel and again 2 blotting papers (without any bubbles), 
was laid in a "Semi-dry" Electroblotter. The current was set to 0.8 mA/cm2 for 90 min, 
for protein transfer. The negatively charged proteins will migrate from the gel on top 
in the direction of the anode at the bottom and transfer onto the PVDF-membrane 
placed underneath the gel. 
2.2.8.4. Immunodetection of proteins
After transferring the proteins, the PVDF-membrane was washed for 5 min in 1x T-
TBS buffer, and then blocked in blocking buffer for 1 hour at room temperature or 
overnight at 4°C. The membrane was then washed for 5 min in 1x T-TBS buffer and 
incubated with the primary antibody (e.g.: P-ERK, 1:200 in blocking buffer) for 1 hour 
at room temperature or overnight at 4°C. After washing three times (5 min each) in 1x 
T-TBS buffer, the membrane was incubated with the secondary antibody solution 
(e.g.: HRP-conjugated anti-mouse monoclonal antibody, 1:1000 diluted in blocking 
buffer) for 1 hour at room temperature.
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2.2.8.5. Enhanced Chemiluminescence (ECL) reaction
The membrane was washed three times, as before (5 min each) in 1x T-TBS buffer 
and once in 1x TBS, then incubated for 1 min in ECL (enhanced chemiluminescence 
ECL) solution which was prepared according to the manufacturer’s instructions. After 
1 min, the membrane was laid between a glass plate and a clear plastic membrane, 
into a photo cassette. A light sensitive film was then placed on top of the membrane 
and exposed for 1-5 min or longer. The film was then developed in a developing 
machine.
In order to detect the ERK2 protein (as a loading control), the previously attached 
antibody was stripped from the membrane by placing it in with 20ml stripping solution 
(Roti-Free, ready-to-use Stripping Buffer, Roth) and incubating for 60 min at 37°C. 
After washing with 1x T-TBS buffer for 5 min, the membrane was incubated in 
blocking buffer for 1 hour at room temperature. After a 5 min wash in 1x T-TBS buffer 
the membrane was incubated with anti ERK2 monoclonal antibody (1:500 diluted in 
blocking buffer) solution for 1 hour at room temperature or overnight at 4°C. After 
three times (5 min/each) washing with T-TBS, the membrane was incubated with the 
secondary antibody solution (e.g.: HRP-conjugated anti-mouse monoclonal antibody, 
1:1000 diluted in blocking buffer) for 1 hour at room temperature. Subsequently the 
membrane was washed as before three times in 1x T-TBS buffer and one more time 
in 1x TBS, and incubated for 1 min in ECL solution and further analysed as before.
2.2.8.6. Quantification of protein bands
Protein bands exposed on the film were scanned at 800 dpi and the picture was 
saved in grey scale as a TIFF file. The intensity of protein bands was 
densitometrically determined by means of PC-BAS software. Both P-ERK and ERK2 
bands were analysed. For normalisation, the lowest band value measured for ERK2 
(loading control) was set to one and divided by all other band values of ERK2. This 
gave a ratio (factor) value for each band to which each corresponding P-ERK band 
value was multiplied. This calculation was calculated to normalize the amount of P-
ERK by the amount of ERK-protein loaded for each sample. 
2.2.9. NF-B analysis
NF-B activity was measured by commercially available kit (TransAM from 
ActiveMotif). This kit uses an ELISA based high-throughput screening system in 
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which 96-well plates are covered with immobilized oligonucleotides containing an NF-
B (5’-GGACTTTCC-3’) consensus binding sequence. Only the active form of NF-B 
will bind to this site. Also, the primary antibodies used then to detect NF-B will 
recognise an epitope on p65 that will only be accessible when NF-B is active and 
bound to the target DNA. A secondary HRP-conjugated antibody is then used for 
colorimetric analysis via spectrophotometry. The sample can be either analysed from 
whole-cell or nuclear extracts. The detection limit for this assay is < 0.5g of cell 
extract or < 0.4ng of recombinant p65 protein/well.
For our study lysates were prepared from infected and treated A549 cells, as 
mentioned before (2.2.1.3.), and collected for further analysis. Assay was performed 
according to manufacturer’s protocol and analysed by ELISA reader at 450nm 
wavelength.
2.2.10. Cytokine analysis
Suspension protein arrays (multiplex bead immunoassay) are designed in a 
capture solid sandwich immunoassay format and permit high throughput of multiple 
markers in individual samples. The system employs colour-coded beads as the solid 
support, each of which is conjugated (covalently bound) with capture antibodies. 
These antibodies will react with the specific analyte (cytokine) of interest from the 
unknown sample or standard. After a series of washing steps to remove unbound 
protein, detector antibodies (biotinylated) are allowed to react with the beads, 
followed by addition of streptavidin-phycoerythrin (streptavidin-PE) – (Biorad) or an 
R-Phycoerytherin (RPE) – (Biosource), which binds to the biotinylated detection 
antibodies. The spectral properties of each bead are then monitored with the 
Luminex 100TM instrument. The constituent of each well is drawn up into the flow-
based instrument which measures each specific reaction based on bead colour and 
fluorescence. Results are calculated by interpolation from the standard curves.
Supernatants from infected and control samples were collected at the respective 
times and analyzed for cytokine expression. Human IL-8, IL-6, MCP-1 and RANTES 
were analysed by a multiplex cytokine array kit (Biorad), mouse KC (mouse analogue 
of human IL-8), IL-6, MCP-1 and RANTES were analysed by a multiplex cytokine 
array kit (Biosource, Invitrogen). Both were performed according to manufacturer’s 
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instructions. For human and mouse IFN analysis, the supernatants were measured 
with commercially available ELISA kits (Biosource, Invitrogen), according to 
manufacturer’s instructions. 
2.2.11. Mice 
C57BL/6 mice (weight of 18-21g) were purchased from Charles River Laboratories 
(Sulzfeld, Germay). Mice were bred under specific pathogen-free (SPF) conditions. 
All experiments were approved by the local government committee of Giessen.
2.2.12. Mice primary cell isolation
Briefly, mice primary alveolar epithelial cells (AECs) were isolated as previously 
described (Corti et al., Am J Respir Cell Mol Biol, 1996) but with some modifications. 
C57BL/6 mice were euthanised by an overdose of isoflurane and exsanguinated by 
cutting the inferior vena cava. Lungs were then perfused with 20 ml of sterile HBSS 
via the right ventricle until they were clean of blood. A shortened 21-gauge cannula 
was then firmly fixed to the exposed trachea through a small incision performed on 
the trachea. 1.5 ml of sterile dispase (enzyme used for digestion) was then applied 
through the needle into the lungs followed by 500l of sterile 1% low melting agarose 
in PBS (37oC). After 2 min of incubation, the lungs were removed into a 15ml tube 
containing 2ml of dispase and allowed to incubate for a further 40 min at RT. The 
lungs were then placed in a culture dish containing DMEM/2.5% HEPES 
buffer/0.01% DNase (also enzyme used for digestion), and the tissue was carefully 
dissected from the airways and large vessels. The cell suspension was successively 
filtered (first through a 100M then through 40M mesh filter membranes and finally 
through a 20M filter paper) to obtain a single cell suspension and resuspended in 
10ml of complete DMEM media. The cells were then incubated with biotinylated rat 
anti-mouse CD16/32 and rat anti-mouse CD45 mAbs (specific leukocyte antibodies) 
for 30 min at 37oC. After this period, cells were washed and incubated with 
streptavidin-linked MagneSphere Paramagnetic Particles for 30 min at RT with gentle 
rocking, followed by magnetic separation of contaminating leukocytes for 15 min. The 
purity of freshly isolated mice primary alveolar epithelial cells (AECs) in the 
supernatant was always >90% (assessed by trypan blue dye exclusion – see section 
2.2.3.2.). Cells were then seeded on 24-well cell culture plates at a density of 4 x 105
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cells/well and grown to 90% confluence for 2 days with complete DMEM media. On 
day 2 cells were washed and serum starved with 0.2% FCS and left until day 3, upon 
which they were submitted to virus infection, as described above.
2.2.13. in vivo mice experiments
Mice were either infected intra-tracheally with 500PFU of influenza virus A/Puerto-
Rico/8/34 (H1N1; PR8) diluted in sterile PBS in a total volume of 70l or with 70l 
sterile PBS (mock controls). Mice were treated intra-peritoneally with inhibitors (Bay 
or U0126) or solvent controls (DMSO, DMSO/Cremophor EL – see below) every 24h 
until day of sacrifice, starting at 24h before infection. Mice were sacrificed on day 2 or 
5 by an overdose of isofluorane. After opening the abdominal cavity the peritoneum 
was cut open and blood was taken from the vena cava inferior (+/- 400l). For the 
bronchoalveolar lavage (BAL) fluid, the trachea was exposed, and a small incision 
was made to insert a 21-gauge cannula which was then firmly fixed, the lungs were 
then washed with 1ml (4 x 250l PBS) collected and analysed for virus titres and 
cytokines. All samples were kept at -80oC, until further analysis.
2.2.14. Statistical analysis
Each point corresponds to the mean +/- S.D. of the indicated experiments. The 
statistical significance of differences between the indicated groups was tested using 
the unpaired Student’s t test with a threshold of p: significant * < 0.5; very significant 
** <0.01; and very very significant *** < 0.001.
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3. Results
Human alveolar epithelial cell line (A549 cells)
Since activation of both the NF-B and the Raf/MEK/ERK pathway seem to be 
important for virus survival as well as immune regulation, I wanted to analyse the 
effect of inhibiting these pathways in human alveolar epithelial cells, in order to 
reduce both virus replication and cytokine induction, simultaneously, in an attempt for 
an anti-viral therapy.
For this purpose I chose a specific IKK inhibitor, Bay 11-7082, and a highly specific
MEK inhibitor, U0126. Bay 11-7082 (Bay) blocks activation of the NF-B pathway by 
selectively inhibiting TNF- inducible phosphorylation of IB
(www.calbiochem.com), whereas U0126 is a selective inhibitor of MEK [284] and 
therefore inhibits downstream activation of the Raf/MEK/ERK pathway.
3.1. Viability of A549 cells upon treatment with specific inhibitors
To ensure that treatment with these inhibitors would not affect cell viability, an MTT 
assay was performed. This assay measures cellular proliferation by a colorimetric 
technique which correlates to mitochondrial enzyme activity (reductases). (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MTT) is taken up by cells and 
can be reduced either enzymatically (by mitochondrial dehydrogenase/reductase 
enzymes) or through direct interaction with NADH, which is reduced to NADPH. This 
reaction only takes place when enzymes are active in living cells and therefore 
conversion is directly related to number of viable cells and can be analyzed 
photometrically in an enzyme-linked immunosorbent assay (ELISA) reader. 
In order to investigate pulmonary epithelial cells which are the primary targets of IAV 
infection in humans [110, 111], the human alveolar epithelial cell line (A549) was
treated for different time points with the respective inhibitors at the concentrations of 
25M (Bay) or 50M (U0126) and a control (untreated) or solvent (DMSO) in the 
according amount. 
Results show that the percentage of viable cells (Figure 3.1), was not affected by 
treatment with the inhibitors tested at concentrations of 25M (Bay) or 50M 
(U0126), demonstrating that these concentrations were not toxic for the cells. Cell 
viability was maintained for up to 48h post treatment.
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Figure 3.1: Viability test on A549 cells. A549 cells were treated with the respective inhibitor 
concentrations (A) Bay at 25µM and (B) U0126 at 50µM, incubated for 6, 8, 10, 24 and 48h at 
37°C/5%CO2 and tested for viability by MTT assay. All groups were assayed with a sample number of 
at least 16.
3.2. Virus infection induces the NF-B signal cascade in A549 cells and Bay 11-
7082 can inhibit this activation as well as decrease virus titres
Infection of cells with IAV has been reported to lead to activation of NF-B pathway 
[222, 223]. Also IAV induction of NF-B has been correlated to increase in 
expression of pro-inflammatory factors [232, 233]. Contradicting this alluded anti-viral 
effect of NF-B activation in IAV infection, other studies have shown that the 
activation of this pathway is extremely important for efficient viral propagation [138, 
139, 234] representing thus a pro-viral function. Since the aim of this study was to 
modulate both virus replication as well as virus-induced cytokine production 
simultaneously, this pathway seemed a perfect target.
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3.2.1. Virus-induced NF-B activation can be inhibited by Bay 11-7082
In order to investigate whether A/FPV/Bratislava/79, H7N7, (FPV) and A/PR/8/34, 
H1N1, (PR8) could also induce the NF-B signalling cascade in A549 cells, cells 
were infected with either FPV or PR8 at a moi=1, and lysates were obtained. Activity 
was monitored at 6 and 8h post infection (p.i.) via an ELISA oligonucleotide based 
method. 
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Figure 3.2.1: Virus-induced NF-B activity can be reduced by Bay. A549 cells were infected with 
FPV (A) or PR8 (B) (moi=1), and incubated for different time points at 37°C/5%CO2 with DMSO or 
with Bay 11-7082 (25µM). Cell lysates were then used to analyse NF-B activity by an ELISA based 
oligonucleotide method. The results are representative of three independent experiments. p values (* 
< 0.5; ** <0.01; *** < 0.001) are given in comparison to infected cells without inhibitor treatment.
Both viruses led to NF-B activation, and activity was shown to be decreased upon 
incubation with the specific IKK inhibitor, Bay 11-7082 (25M), for both FPV by 70% 
(Figure 3.2.1(A)) and PR8 by 80% (Figure 3.2.1(B)).
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3.2.2. Virus titres can be inhibited by Bay 11-7082
As I also wanted to affect virus propagation in this setting by blocking this pathway, 
analysis was performed on the supernatants from infected A549 cells, at different 
time points (4, 6, 8 and 10h p.i.) treated or untreated with Bay inhibitor, for virus 
titres. 
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Figure 3.2.2: Virus titres can be reduced by Bay. A549 cells were infected with FPV (A) or PR8 
(B)(moi=1), and incubated for different time points at 37°C/5%CO2 with DMSO or with Bay 11-7082 
(25µM). Virus titres were analysed from supernatants of the according sample by FFU assay. The 
results are representative of three independent experiments. p values (* < 0.5; ** <0.01; *** < 0.001) 
are given in comparison to cells infected without inhibitor treatment.
As depicted in Figure 3.2.2, a significant decrease was observed in virus titres upon 
treatment, using the specific IKK inhibitor (Bay at 25M). This was true for both the 
avian (FPV) by 70-50% and human viruses (PR8) by 65-80% analysed in these 
experiments. 
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3.3. Virus infection induces the Raf/MEK/ERK signal cascade in A549 cells and 
U0126 can inhibit this activation as well as decrease virus titres
Influenza virus infection of cultured cells has been shown to lead to the activation of 
the classical Raf/MEK/ERK (MAPK) signalling cascade. As also previously 
demonstrated activation of this pathway has mainly been linked to efficient influenza 
virus propagation [132, 182, 186].
3.3.1. Virus-induced Raf/MEK/ERK can be reduced by U0126
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Figure 3.3.1.A: FPV-induced ERK activity can be reduce by U0126. A549 cells were infected with 
FPV (moi=1) and incubated for different time points at 37°C/5%CO2 with DMSO or with U0126 
(50µM). At the respective time points (4, 6, 8, and 10h) cell lysates were prepared and later analysed 
by Western blot analysis, using a specific anti-P-ERK monoclonal mouse antibody for the detection of 
activated ERK. Respective bands of three independent experiments were quantified and relative ERK 
activation was calculated and normalized to the loading control (ERK2).  p values (* < 0.5; ** <0.01; *** 
< 0.001) are given in comparison to infected cells without inhibitor treatment.
In order to determine whether FPV and PR8 also have the capacity to induce activity 
of the Raf/MEK/ERK signalling cascade in A549, cells were infected with either virus 
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at a moi=1, and activity was monitored at 4, 6, 8 and 10h p.i. via western blot 
analysis. 
As demonstrated, both viruses were able to lead to ERK activation, with a gradual 
increase over time. This activity was shown to be dramatically decreased upon 
incubation with the specific MEK inhibitor, U0126, for both FPV by 60-80% and PR8 
by 85-95% viruses (Figure 3.3.1.A and 3.3.1.B).
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Figure 3.3.1.B: PR8-induced ERK activity can be reduce by U0126. A549 cells were infected with 
PR8 (moi=1). At the respective time points (4, 6, 8, and 10h) cell lysates were prepared and later 
analysed by Western blot analysis, using a specific anti-P-ERK monoclonal mouse antibody for the 
detection of activated ERK. Respective bands of three independent experiments were quantified and 
relative ERK activation was calculated and normalized to the loading control (ERK2). ERK activation 
from mock-infected cells was accordingly set to 1. p values (* < 0.5; ** <0.01; *** < 0.001) are given in 
comparison to infected cells without inhibitor treatment.
3.3.2. Virus titres can be inhibited by U0126
Now, to identify if the inhibition induced by U0126 on ERK activity, could lead to 
reduced virus replication in A549 cells, supernatants were analysed for virus titres 
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(by FFU assay) from FPV or PR8 (moi=1) infected A549 cells, at different time points 
(4, 6, 8 and 10h p.i.). In agreement with previous results [132], I was able to 
demonstrate that inhibition of ERK activity, using the specific MEK inhibitor U0126 (at 
50M), effectively reduced FPV by 75-60% and PR8 by 65% virus titres in human 
alveolar epithelial (A549) cells (Figure 3.3.2).
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Figure 3.3.2: Virus titres are decreased by U0126 treatment. A549 cells were infected with avian 
FPV (A) or human PR8 (B) (moi = 1), and treated with solvent (DMSO) or U0126 (50M) for different 
time points (4, 6, 8 and 10h). The supernatants were collected at the different time points and later 
analysed for virus titres by FFU assay. All groups were assayed in triplicate. p values (* < 0.5; ** 
<0.01; *** < 0.001) are given in comparison to infected cells without inhibitor treatment.
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3.4. Bay 11-7082 and U0126 can decrease influenza A virus-induced cytokine 
production in A549 cells
Since I could show that in the A549 cell system, both pathways could be activated by 
either virus (FPV and PR8), and that I could efficiently reduce both activation of the 
respective pathways as well as virus titres with specific inhibitors (Bay – IKK inhibitor 
and U0126 – MEK inhibitor), I now wanted to investigate the effect of these inhibitors 
in virus induced cytokine secretion in A549 cells. 
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Figure 3.4.1: Virus-induced cytokine release is decrease upon inhibitor treatment. A549 cells 
were infected with either FPV or PR8 (moi=1), for 1h RT, then incubated for 10h at 37°C. 
Supernatants were analysed for cytokines/chemokines IL-8 (A) and MCP-1 (B), expression by 
Multiplex assay. All groups were assayed in triplicate. p values (* < 0.5; ** <0.01; *** < 0.001) are 
given in comparison to mock vs. infected or infected (–) inh. vs infected (+) inh. treatment.
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To this end A549 cells were infected, as previously described, with FPV, PR8 and 
delNS1 (see below) (moi=1), and supernatants collected at 10h p.i.. The samples 
were always kept at -70oC until further analysis. Cytokine analysis was performed 
using specific immunoarray kits (see methods). 
In these cytokine/chemokine studies the delNS1 virus (a PR8 virus with a deleted 
NS1 segment) was used as a positive control, since the NS1 protein of influenza 
virus, as previously explained, has been linked to down-regulation of host immune 
responses, mainly to the attenuation of IFN production [66, 67]. 
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Figure 3.4.1: Virus-induced cytokine release is decrease upon inhibitor treatment. A549 cells 
were infected with either FPV or PR8 (moi=1), for 1h RT, then incubated for 10h at 37°C. 
Supernatants were analysed for cytokine/chemokine IL-6 (C) and RANTES (D) expression by 
Multiplex assay. All groups were assayed in triplicate. p values (* < 0.5; ** <0.01; *** < 0.001) are 
given in comparison to mock vs. infected or infected (–) inh vs. infected (+) inh treatment.
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Expression profiles of cytokines/chemokines varied depending on the virus used 
(Figure 3.4.1). FPV had no effect on IL-8 (A), MCP-1(B) and IL-6 (C), but lead to an 
increase in RANTES (D) production, whereas PR8 was able to induce IL-8 and IL-6, 
and reduce MCP-1 and RANTES expression. What was consistent for all results 
though was that both inhibitors were able to reduce cytokine/chemokine production. 
In the case of IL-8, the U0126 was a better inhibitor than Bay 11-7082.
The delNS1 virus was also found to increase IL-6 production, but had no effect on 
the other cytokines tested (IL-8, MCP-1 and RANTES) at 10h p.i. 
IFN secretion was measured by use of a specific human ELISA kit. I was unable to 
detect IFN, both in FPV as well as PR8 virus infection and also at different time 
points tested (10 and 24h p.i.) (Figure 3.4.2). But, as expected, the delNS1 virus was 
able to efficiently induce secretion of this cytokine. 
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Figure 3.4.2: IFN induction in A549 cells. A549 cells were infected with either FPV, PR8 or delNS1 
(a NS1 deletion mutant of PR8 – used as a positive control) (moi=1), then incubated for 10 and 24h at 
37°C/5%CO2. Supernatants were collected and IFN analysed by commercial available human IFN
ELISA kit. All groups were assayed in triplicate.
3.5. FPV and PR8-induced nuclear RNP export is efficiently blocked by Bay 11-
7082 and U0126 in A549 cells.
As both NF-B and ERK pathway activation have been associated with efficient viral 
nuclear RNP export [132, 181, 234], I decided to confirm these findings in the A549 
system. A549 cells were infected with either FPV or PR8 viruses and treated with 
either inhibitor (Bay or U0126) for different time points (6, 8 and 10h p.i.). At each 
selected time point cells were fixed until further analysis. Evaluation of the 
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intracellular RNP localization was analysed at the different time points by means of 
immunofluorescence with a confocal microscope. 
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Figure 3.5.1: vRNP nuclear export in A549 cells. A549 cells were infected with FPV (moi=1), and 
incubated for 10h p.i. at 37°C/5%CO2 with normal media or treated with DMSO, Bay 11-7082 (25µM) 
or U0126 (50M). Cells were fixed and analysed by immunofluorescence with a confocal microscope.
Representative pictures of three independent experiments are shown.
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Figure 3.5.2: vRNP nuclear export in A549 cells. A549 cells were infected with PR8 (moi=1), and 
incubated for 10h p.i. at 37°C/5%CO2 with normal media or treated with DMSO, Bay 11-7082 (25µM) 
or U0126 (50M). Cells were fixed and analysed by immunofluorescence with a confocal microscope. 
Representative pictures of three independent experiments are shown.
Results demonstrate that in A549 cells both avian (FPV) as well as human (PR8) 
influenza virus show nuclear RNP export, however, upon inhibitor treatment (with 
Bay or U0126), the RNP export was significantly affected as seen at 10h p.i. (Figure 
3.5.1 and 3.5.2). The results confirm that the activation of both NF-B as well as 
Raf/MEK/ERK pathways is necessary for efficient viral nuclear RNP export.
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Primary mice alveolar epithelial cells (AECs)
The findings so far had demonstrated that both inhibitors (Bay and U0126) tested  for 
the two pathways, NF-B and ERK,  were efficient at decreasing virus titres as well 
as simultaneously reducing virus-induced cytokine release in A549 cells, thus, I 
decided to test this theory in a system closer to the in vivo situation. For this I chose
to analyse mice primary alveolar epithelial cells (AECs) upon influenza virus infection 
and treatment with the previously selected inhibitors. 
Isolation of type II AECs are characterized by pro-SPC accumulation in the cells 
visualized by antibody staining. By day 3 or 4 (day of infection), the main type of 
AECs present are of type I, characterized by loss of pro-SPC staining and an 
abundance/increase of presence of T1 staining (specific marker antibody for type I 
alveolar epithelial cells).
At this point it is important to mention that all the work concerning primary cell 
isolation was kindly performed by Lidija Cakarova (PhD student) from Prof. Juergen 
Lohmeyer’s laboratory in Medical Clinic II, in Giessen. 
Mice were bred under specifc pathogen-free (SPF) conditions. All mice experiments 
were approved by the local government committee of Giessen.
3.6. Viability of mice primary alveolar epithelial cells upon treatment with 
specific inhibitors
To determine the optimal inhibitor concentration for experiments in AECs, a 
concentration curve was drawn for the inhibitors Bay 11-7-82 and U0126. Due to the 
obvious difficulty and ethical reasons in obtaining primary cells, an alternative assay 
for cell viability was chosen instead of the traditional MTT assay. WST-1 assay 
permits cell viability analysis during the course of the experiment (see methods), and 
given the amount of AEC cells available, was the most reasonable choice for these 
tests. 
Previous initial results had proven that the inhibitor concentrations (Bay – 25M and 
U0126 – 50M) used in A549 cells were toxic for these AECs. Therefore, AECs were 
treated for different time points with the respective inhibitors at different decreasing 
concentrations of Bay (15; 10; 7.5; and 5M) or U0126 (40; 30; 20 and 10M) and a 
control (PBS) or solvent (DMSO). Cell viability was tested for up to 30h post 
treatment. 
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Results (Figure 3.6) demonstrate that none of the concentrations tested here, from 
both inhibitors (Bay or U0126), had any compromising effect on AEC viability, 
demonstrating that these concentrations were not toxic for the cells. I therefore used 
in the following experiments the highest non-toxic concentration for both inhibitors, 
namely Bay – 15M and U0126 – 40M.
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Figure 3.6: Viability test on mice primary alveolar epithelial cells. Primary mice AECs were 
treated with Bay (A) or U0126 (B) inhibitor at indicated concentrations, further incubated for 10, 24 
and 30h at 37°C/7.5%CO2 and tested at the indicated time points for viability by WST-1 method. All 
groups were assayed in triplicate.
3.7. Viability of mice primary alveolar epithelial cells upon treatment with 
specific inhibitors during the course of infection
As mentioned above, one can analyse cell viability during the experimental 
procedure, when using the WST-1 method. I therefore decided to evaluate the 
viability of AECs during the course of a viral infection. A zero hour (before infection) 
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WST-1 test performed, and then continued, as explained earlier, by infecting for 1 
hour at RT. Following this one hour incubation, inoculum was aspirated and media 
with solvent or inhibitors was added to wells, for different time points (10, 24 and 32h 
p.i.). At each time point the media was removed and kept separately at RT while 
performing the WST-1 assay. After the one hour incubation of the cells with the WST-
1 media, the original media was returned to the wells and the experiment continued 
until the 32 h time point.
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Figure 3.7: Viability test on mice primary alveolar epithelial cells during infection. Primary mice 
AECs were infected with either FPV (moi=0.1) or PR8 (moi=0.01) and incubated for 10, 24 and 32h at 
37°C/7.5%CO2. At each time point cells were analysed for viability according to WST-1 protocol (refer 
to Methods). Results show for FPV (A) and PR8 (B) with Bay at 15M. All groups were assayed in 
triplicate.
Figure 3.7 confirms previous findings, showing no toxic effect of the inhibitors during 
the course of the infection, as seen by the mock treated AECs. It was interesting to 
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observe that upon infection and treatment, the Bay inhibitor could actually increase 
cell survival of infected and Bay treated cells compared to infected and solvent 
(DMSO) treated cells. This was observed with both FPV (A) and PR8 (B) viruses at 
24 and 32h p.i., although more apparent and significant at 24h p.i. This effect was not 
observed in the cells treated with the U0126 inhibitor.
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Figure 3.7: Viability test on mice primary alveolar epithelial cells during infection. Primary mice 
AECs were infected with either FPV (moi=0.1) or PR8 (moi=0.01) and incubated for 10, 24 and 32h at 
37°C/7.5%CO2. At each time point cells were analysed for viability according to WST-1 protocol (refer 
to Methods). Results show for (C) FPV and (D) PR8 with U0126 at 40M. All groups were assayed in 
triplicate.
3.8. Both Bay 11-7082 nd U0126 can decrease virus titres in mice primary AECs
In earlier experiments I could demonstrate that both inhibitors (Bay and U0126) were 
capable of inhibiting virus replication in A549 cells. The aim now was to test this 
effect on primary cells, and specifically in mice primary alveolar epithelial cells. 
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To this end, AECs were infected with FPV (moi = 0.1) or PR8 (moi = 0.01) and 
treated with DMSO, Bay (15M) or U0126 (40M) for different time points (10, 24 
and 32h p.i.). Supernatants were collected at each time point, and analysed for virus 
titres (by FFU assay).
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Figure 3.8: Virus titres in mice primary alveolar epithelial cells upon treatment. Primary mice 
AEC‘s were infected with either FPV (moi=0.1) (A) or PR8 (moi=0.01) (B), and treated with DMSO 
(solvent), Bay (15M) or U0126 (40M) and incubated for 24 and 32h at 37°C/7.5%CO2. 
Supernatants were collected and analysed for virus titre by FFU assay. All groups were assayed in 
triplicate. p values (* < 0.5; ** <0.01; *** < 0.001) are given in comparison to cells infected (–) inh. vs. 
infected (+) inh. treatment.
Confirming earlier A549 results, both the IKK inhibitor (Bay 11-7082) and the MEK 
inhibitor (U0126), were able to efficiently and significantly decrease virus titres in 
AECs (Figure 3.8). Virus titres were reduced with Bay by 60-40% in FPV and 75-85% 
in PR8, while U0126 reduced FPV titres by 60% and PR8 by 85%. This 
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demonstrated that activity of both NF-B as well as Raf/MEK/ERK pathway is also 
important for viral propagation in mice primary alveolar epithelial cells.
3.9. Bay 11-7082 and U0126 can decrease influenza A virus-induced cytokine 
production in mice primary AECs
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Figure 3.9.1 (A and B): Cytokine induction in primary alveolar epithelial cells. Primary mice 
AECs were infected with either FPV (moi=0.1), PR8 (moi=0.01) or delNS1 (moi=0.1) and treated with 
either solvent (DMSO), Bay (15M) or U0126 (40M) for 10h at 37°C/7,5%CO2. Supernatants were 
collected and analysed for KC (mouse analogue for human IL-8) (A) or MCP-1 (B) by specific 
multiplex assay kits. All groups were assayed in triplicate. p values (* < 0.5; ** <0.01; *** < 0.001) are 
given in comparison to mock vs. infected or infected (–) inh. vs. infected (+) inh. treatment.
I was now able to demonstrate that inhibiting NF-B and Raf/MEK/ERK pathways by 
use of specific inhibitors led to reduction of virus titres in A549 as well as in mice 
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primary alveolar epithelial cells (AECs). I could also show that in A549 cells, inhibition 
of these pathways could reduce virus-induced cytokine production. I now wanted to 
prove whether this effect would still hold true for AECs. 
For this purpose AECs were infected as before with either FPV (moi = 0.1) or PR8 
(moi = 0.01) and treated with solvent (DMSO) or the specific inhibitors (Bay or 
U0126) and analysed cytokine/chemokine secretion from supernatants at 10h p.i..
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Figure 3.9.1 (C and D): Cytokine induction in primary alveolar epithelial cells. Primary mice 
AECs were infected with either FPV (m.o.i.=0.1), PR8 (m.o.i.=0.01) or delNS1 (m.o.i.=0.1) and treated 
with either solvent (DMSO), Bay (15M) or U0126 (40M) for 10h at 37°C/7,5%CO2. Supernatants 
were collected and analysed for IL-6 (C) or RANTES (D) by specific multiplex assay kits. All groups 
were assayed in triplicate. p values (* < 0.5; ** <0.01; *** < 0.001) are given as compared to mock vs. 
infected or infected (–) inh. vs. infected (+) inh. treatment.
As depicted in Figures 3.9.1, FPV was unable to induce KC (the human IL-8 
analogue in mice) (A), MCP-1 (B) or IL-6 (C) secretion whereas it slightly increased 
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RANTES (D) production at 10h p.i.  However PR8 led to a reduction in KC whereas 
MCP-1 was only slightly increased. PR8 was, however, able to significantly induce IL-
6, but had no effect on RANTES induction as compared to mock at 10hp.i.. Both 
inhibitors were, in any case, able to efficiently reduce cytokine production for both 
viruses. The delNS1 was also able to induce increase in MCP-1 and IL-6 in mice 
primary alveolar epithelial cells (AEC), but had no effect on KC and RANTES.
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Figure 3.9.2: IFN induction in primary alveolar epithelial cells. Primary mice AECs were infected 
with either FPV (moi=0.1), PR8 (moi=0.01) or delNS1 (moi=0,1) and treated with either solvent 
(DMSO), Bay (15M) or U0126 (40M) for 10h at 37°C/7,5%CO2. Supernatants were collected and 
analysed for IFN by ELISA. All groups were assayed in triplicate. p values (* < 0.5; ** <0.01; *** < 
0.001) are given as compared to mock vs. infected or infected (–) inh. vs. infected (+) inh. treatment.
IFN evaluation was accomplished by analyzing supernatants using a specific mouse 
ELISA kit. As shown in Figure 3.9.2 FPV was able to induce significant IFN
production whereas PR8 lead to a slight increase in this cytokine. As seen before in 
A549 cells delNS1 virus was capable of inducing very high IFN secretion 
(2867pg/ml), again demonstrating the importance of the NS1 protein in viral defence.
3.10. FPV and PR8 induced nuclear RNP export is efficiently blocked by Bay 11-
7082 and U0126 in AECs.
As both NF-B and ERK pathway inhibitors, Bay and U0126 respectively, had been 
previously shown to lead to nuclear RNP retention in A549 cells, and to exclude that 
this effect was exceptional to established permanent cell lines, as also previously 
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observed by others [132, 181, 234], I decided to confirm these findings in mice 
primary alveolar epithelial cells. AECs were therefore infected with either FPV or PR8 
viruses (moi = 0.02) and treated with either DMSO (solvent), Bay (15M) or U0126 
(40M) for 10h p.i.. At the selected time point cells were fixed and further analysed 
for the intracellular RNP localization by means of immunofluorescence with a 
confocal microscope. 
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Figure 3.10.1: vRNP nuclear export in mice primary alveolar epithelial cells. AECs were infected 
with FPV (moi=0.02), and incubated for 10h p.i. at 37°C/7.5%CO2 with normal media or treated with 
DMSO, Bay 11-7082 (15µM) or U0126 (40M). Cells were fixed and later analysed by 
immunofluorescence with a confocal microscope. Representative pictures of three independent 
experiments are shown.
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Figure 3.10.2: vRNP nuclear export in mice primary alveolar epithelial cells. AECs were infected 
with PR8 (moi=0.02), and incubated for 10h p.i. at 37°C/7.5%CO2 with normal media or treated with 
DMSO, Bay 11-7082 (15µM) or U0126 (40M). Cells were fixed and later analysed by 
immunofluorescence with a confocal microscope. Representative pictures of three independent 
experiments are shown.
Results demonstrate that in AECs, influenza virus induced-nuclear RNP export at 
10h p.i. was impaired upon inhibitor treatment (with Bay or U0126) (Figure 3.10.1 
and 3.10.2). Taken together the results demonstrate that the effect of blocking RNP 
nuclear export by inhibiting NF-B or Raf/MEK/ERK pathways, till now only shown in 
permanent cell lines, could be reproduced in mice primary alveolar epithelial cells.
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Cocktail treatment
Since both inhibitor systems had proven to inhibit virus-induced cytokine induction as 
well as virus propagation, simultaneously, both in human alveolar epithelial cell lines
(A549) as well as in mice primary alveolar epithelial cells (AECs), I wished to 
determine whether the combination of both inhibitors used in lower concentration in a 
“cocktail” could further enhance this effect. The aim was to reduce single inhibitor 
treatment by a combined therapy, therefore lower inhibitor concentration were tested 
in combination. 
3.11. Cell viability in A549 cells with combination treatment (Bay and U0126). 
To test this hypothesis, evaluation of combination treatment concentrations that 
would not compromise cell viability had to be analysed. So as not to sacrifice mice 
unnecessarily, A549 cells were first analysed. Again an MTT assay was performed 
on A549 cells, as before, treated with different combinations of lower inhibitor 
concentrations for different time points.
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Figure 3.11: Viability of A549 cells with combination treatment (Bay + U0126). A549 cells were 
treated with the respective inhibitor cocktail concentration (Bay/U0126, B/U-1:15M/30M; B/U-
2:10M/30M; B/U-3:10M/25M; B/U-4:7.5M/25M) , incubated for 10, 24 and 48h at 37°C/5%CO2 
and tested for cell viability by MTT assay. Mean and standard deviation is representative of sample 
number of 16.
Results demonstrate that all the concentrations tested up to 24h p.i. had no toxic 
effect on the cells, and only had adverse effects at 48hp.i. on cell viability (Figure 
3.11). Therefore I decided to perform further tests with two of the highest 
concentration.
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3.12. Virus titres treated with combination treatment (Bay and U0126).
To evaluate whether a combination of the inhibitors could further decrease virus 
propagation, I infected A549 cells with either FPV or PR8 (moi =1) and treated them 
with DMSO or the two previously selected inhibitor “cocktails” (Bay-15M/U0126-
30M and Bay-10M/U0126-30M) (see section 3.11.).
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Figure 3.12: Virus titres with combined inhibitors on A549 cells. A549 cells were infected with 
FPV (A) or PR8 (B) (moi=1) and treated with the respective inhibitor cocktail concentration (Bay-
25M; U0126-50M; Bay/U0126, B/U-1:15M/30M; B/U-2:10M/30M) and incubated for 8 and 10h 
at 37°C/5%CO2 and virus titres were analysed from supernatants by FFU assay. All groups were 
assayed in triplicate.
As seen in Figure: 3.12, there was no significant enhanced decrease using the lower 
combination treatment (Bay-15M/U0126-30M and Bay-10M/U0126-30M) in the 
3. Results
81
observed virus titre when comparing to results with single inhibitor treatment (Bay –
25M or U0126 – 50M).
3.13. Cell viability in AECs with combination treatment (Bay and U0126). 
Not wanting to abandon this hypothesis entirely in regard to combination treatment, 
although the observed results in A549 cells were not promising, I decided to evaluate 
this effect in primary alveolar epithelial cells, since previous results from cytokine 
analysis had demonstrated that the effects seen in A549 cells not always 
corresponded to AEC results. 
For this reason viability tests with several combination treatments were performed on 
AECs and cell toxicity analysed with the WST-1 method.
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Figure 3.13: Mice primary alveolar epithelial cells viability test (WST assay) with combination 
treatment. Primary mice AECs were treated with the respective inhibitor cocktail concentrations 
(Bay/U0126, B/U-1:15M/30M; B/U-2:10M/30M; B/U-3:10M/25M; B/U-4:7.5M/25M) and 
incubated for 10, 24 and 32h at 37°C/7.5%CO2. Supernatants were then collected and cells were then 
washed once and 300µl of WST-1 media was added for 1h and incubated at 37°C/7.5%CO2, and 
further analysed according to WST-1 protocol. All groups were assayed in triplicate.
As shown in Figure: 3.13 (above), all the inhibitor “cocktails” tested (even the lowest 
concentrations) had very toxic effects on cells as early as 10h after treatment. For 
this reason, and the fact that in A549 cells the results with the combined treatment 
were also not alluring, I decided to abandon this investigation.
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in vivo mice experiments
All the results so far suggested that the hypothesis to decrease both virus titres and
virus-induced cytokine secretion was valid in my experimental cell culture setup. This 
idea is thought to be meaningful in “real life” situations specially when considering the 
reports on HPAIV, such as the H5N1. These reports associate pathology and 
symptoms with increase inflammatory responses as well as high viral loads [110, 
111, 115, 126]. Since the opportunity to analyse these effects in an in vivo mouse 
model arose I decided to take this approach to study a closer to “real-life” situation. 
Previous studies using mice in vivo experiments have shown that the A/PR/8/34 virus 
induces cytokine/chemokine expression and is lethal in mice [242, 286, 287]. For this 
reason and the one stated above, the next step was to study the effect of the specific 
IKK and MEK inhibitors (Bay and U0126, respectively) in an in vivo mouse model, 
using this A/PR/8/34 virus strain as a “proof of principle”.
Again, in this situation, it is important to mention, that most of the mice handling was 
performed by either Katrin Hoegner or Susanne Herold, from the laboratory of Prof. 
Joergen Lohmeyer, in Medical Clinic II, Giessen.
Mice were bred under specific pathogen-free (SPF) conditions. All mice experiments 
were approved by the local government committee of Giessen.
3.14. C57BL/6 mice 
To determine whether the results observed for A549 as well as primary alveolar 
epithelial cells (AECs) could be reproduced in an in vivo model, in vivo experiments 
were conducted in C57BL/6 mice. 
Previous reports from Susanne Herold (unpublished data) had given some idea on 
viral as well as cytokine kinetics after intratracheal inoculation of C57BL/6 mice with 
the PR8 virus. For this reason the same protocol was maintained, so as not to waste 
unnecessary mice to build up a new kinetics curve. 
Also, previous studies performed by Oliver Planz’s group (Tuebingen, Germany) on 
an appropriate solvent for U0126, gave us a head start as to a means of minimizing 
DMSO solvent application in in vivo experiments. Cremophor EL (CremEL) is a non-
ionic solubilizer and emulsifier and can convert hydrophobic drugs into aqueous 
solutions allowing the drug to be more readily absorbed. By using this oil, we could 
minimize DMSO solvent administration.
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Report on U0126 intraperitoneal application in mice had been shown earlier by Duan 
et al. [288] in a mouse asthma model. I decided to use the same concentration of 
inhibitor in this model therefore a dose of 30mg/kg mouse was selected and applied, 
dissolved in DMSO/CremEL (see methods, section 2.2.13) via intraperitoneal 
injection to mice every 24h, starting 24h before infection.
For the IKK inhibitor, Bay 11-7082, I decided to administer a concentration based on 
the same molarity ratio used in our previous A549 cell culture experiments. Therefore 
a concentration of 8.2g/kg mouse was used. The amount of DMSO solvent 
necessary for the Bay inhibitor application (7.89l/mouse) was in the range of the 
DMSO present in the U0126 DMSO/CremEL solvent (6l/mouse), and therefore, was 
considered minimal. Bay inhibitor was also administered to mice every 24h starting 
24h before infection.
3.14.1 Bay 11-7082 and U0126 can decrease virus titres in in C57BL/6 mice 
Earlier tests in both A549 as well as AECs demonstrate that both inhibitors (Bay and 
U0126) were capable of inhibiting virus replication in vitro. The aim now was to test 
this effect in an in vivo mouse model. 
Titres from infected solvent treated (DMSO or CremEL/DMSO) mice versus infected 
and inhibitor treated (Bay or U0126) mice, both at day 2 and day 5 p.i., from 
bronchoalveolar lavage fluids (BAL) showed a significant decrease in virus titres 
observed at both time points (as analysed by FFU assay) when administering the 
individual inhibitors (Figure: 3.14). PR8 was effectively reduced by 60% at both time 
points (day 2 and 5) with Bay and by 95% (day 2) and 50% (day 5) with the U0126. 
This demonstrated that activity of both NF-B as well as Raf/MEK/ERK pathway is 
also important for viral propagation in mice. During the course of the treatment there 
no differences were observed in the behaviour and appearance of mice from the 
individual groups.
One can speculate that it could be possible that, by using another route of 
administration as well as further optimized concentrations of the inhibitors, better 
results would be achieved in further decreasing virus titres.
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Figure 3.14: Virus titres in mice treated with inhibitors. Mice were infected intratracheally with 500 
PFU of PR8 in 70µl in PBS (filtered) or mock infected with 70l PBS. Solvent (DMSO or 
DMSO/CremEL), Bay or U0126 were administered intraperitoneally, daily starting at -24h (before 
infection). Mice were sacrificed on day 2 (A) or day 5 (B) p.i., and BAL performed. Virus titres were 
assayed by FFU assay. p values (* < 0.5; ** <0.01; *** < 0.001) of treated mice are given in 
comparison to mock (solvent) treated mice. All groups were assayed in quadruplicate (day 2) or 
triplicate (day 5).
3.14.2 Bay 11-7082 and U0126 can decrease virus induced cytokines in 
C57BL/6 mice
The next step was then to compare the different cytokine/chemokine levels in BAL 
from mock infected versus PR8 infected mice, treated with solvents or with inhibitors.  
TNF- is mainly produced by macrophages and monocytes and it has been 
previously cited to be an important cytokine induced in IAV infections [126, 248, 289], 
for this reason I wanted to include this cytokine analysis in the mice experiments. 
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Both TNF- and IFN were assayed by commercial available specific mouse ELISA 
kits and the KC, MCP-1, IL-6 and RANTES with cytokine immunoarray kits.
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Figure 3.15: TNF- results in mice treated with inhibitors. Mice were infected intratracheally with 
500 PFU of PR8 in 70µl in PBS (filtered) or mock infected with 70l PBS. Solvent (DMSO or 
DMSO/CremEL), Bay or U0126 were administered intraperitoneally, daily starting at -24h (before 
infection). Mice sacrificed on day 2 (A) or day 5 (B) p.i. and BAL performed. TNF- was measured 
using a commercial available ELISA kit. p values (* < 0.5; ** <0.01; *** < 0.001) are given in 
comparison to mock vs. infected or infected (–) inh. vs. infected (+) inh. treatment. All groups have a 
number of 3 mice with exception to mock groups of day 5, which were 2 mice per group.
As depicted above (Figure 3.15) at day 2 there was an observed increase in TNF-in 
infected, solvent treated mice as compared to mock infected, although more 
apparent in the solvent (DMSO/CremEL) than in the DMSO group. Both inhibitors 
however were able to decrease TNF- production, but the U0126 seemed to be more 
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effective than the Bay, and reduced TNF- to almost baseline levels. There was no 
significant increase or decrease observed when comparing the groups at day 5.
Results from IFN analysis (Figure 3.16) both at day 2 and day 5, show a significant 
increase in infected, solvent treated mice as compared to mock infected.
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Figure 3.16: IFN results in mice treated with inhibitors. Mice were infected intratracheally with 
500 PFU of PR8 in 70µl in PBS (filtered) or mock infected with 70l PBS. Solvent (DMSO or 
DMSO/CremEL), Bay or U0126 were administered intraperitoneally, daily starting at -24h (before 
infection). Mice were sacrificed on day 2 (A) or day 5 (B) p.i. and BAL performed. IFN was measured 
using a commercial available ELISA kit. p values (* < 0.5; ** <0.01; *** < 0.001) are given in 
comparison to mock vs. infected or infected (–) inh. vs. infected (+) inh. treatment. All groups have a 
number of 3 mice with exception to mock groups of day 5, which were 2 mice per group.
Only the Bay inhibitor treated mice, however, had significantly lower induction 
amounts of this cytokine. This “protective” effect of Bay, although not significant was 
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still able to reduce IFN mean values almost to background levels at day 5. The 
standard deviations were sometimes pretty high due to the relative amount of mice 
numbers per group, but the tendency of Bay to reduce IAV-induced IFN was noted. 
There was no significant difference between the solvent (DMSO/CremEL) group and 
the U0126 at both day 2 and 5, nevertheless a tendency was evident.
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Figure 3.17: KC (A) and MCP-1 (B) results in mice treated with inhibitors. Mice were infected 
intratracheally with 500 PFU of PR8 in 70µl in PBS (filtered) or mock infected with 70l PBS. Solvent 
(DMSO or DMSO/CremEL), Bay or U0126 were administered intraperitoneally, daily starting at -24h 
(before infection). Mice were sacrificed on day 5 days p.i., and BAL performed. Cytokines were 
measured using the multiplex bead immunoassay. p values (* < 0.5; ** <0.01; *** < 0.001) are given in 
comparison to mock vs. infected or infected (–) inh. vs. infected (+) inh. treatment. All groups have a 
number of 3 mice with exception to mock groups of day 5, which were 2 mice per group.
KC analysis (Figure 3.17 (A)) from day 5, showed a significant increase in infected, 
solvent (DMSO/CremEL) treated mice as compared to mock infected, whereas the 
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DMSO group only showed a slight tendency for increase. Although there was no 
apparent significant decrease upon inhibitor treatment in both groups (Bay and 
U0126) the tendency for reduction was also noted.
For MCP-1 (Figure 3.17 (B)) the infected groups showed a significant increase in 
production of this cytokine as compared to mock groups. Bay inhibitor treatment also 
seemed to effectively reduce this induction, as compared to the infected DMSO 
treated group. For the U0126 a tendency was also noted here.
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Figure 3.18: IL-6 (C) and RANTES (D) results in mice treated with inhibitors. Mice were infected 
intratracheally with 500 PFU of PR8 in 70µl in PBS (filtered) or mock infected with 70l PBS. Solvent 
(DMSO or CremEL/DMSO), Bay or U0126 were administered intraperitoneally, daily starting at -24h 
(before infection). Mice sacrificed on day 5 days p.i., and BAL performed. Cytokines were measured 
using the multiplex bead immunoassay. p values (* < 0.5; ** <0.01; *** < 0.001) are given in 
comparison to mock vs. infected or infected (–) inh. vs. infected (+) inh. treatment. All groups have a 
number of 3 mice with exception to mock groups of day 5, which were 2 mice per group.
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Both IL-6 (C) and RANTES (D) (Figure 3.18) were up-regulated on day 5 in infected 
mice as compared to mock controls. However, whereas in the case of IL-6 (C), only 
the Bay group showed a significant decrease in production of this cytokine compared 
to the DMSO infected group, in the case of RANTES (D) both inhibitors (Bay and 
U0126) demonstrated a significant effect on reducing this cytokine induction. 
Generally both inhibitors showed a tendency for reducing IAV-induced cytokine 
production in C57BL/6 mice. In the case of Bay treatment it was effective for 
attenuation of most cytokines, although less effective on TNF-. U0126 on the other 
hand was more significant at decreasing TNF-, but always showed a tendency at 
reducing all other cytokines tested (see table of results 3.1).  
Both inhibitors were also similarly effective at reducing virus titres in vitro and in vivo, 
with U0126 being slightly better than Bay.
Taken together both pathways have been demonstrated at being important for both 
virus replication as well as host cell virus-induced defence mechanisms (in the form 
of induced cytokine expression), and treatment with specific NF-B as well as 
Raf/MEK/ERK inhibitors (Bay and U0126, respectively) were shown to be effective at 
simultaneously reducing virus titres and virus-induced cytokine production (see table 
of results 3.1.).
Systems Inhibitors IL-8/KC MCP-1 IL-6 RANTES IFN TNF-
Bay + ++ ++ +++A549 
cells U0126 +++ ++ ++ ++
Bay + ++ +++ + +primary 
AECs U0126 + + +++ - +
Bay ~ ++ + + + ~Mice 
C57BL/6 U0126 ~ ~ ~ + ~ +
Table 3.1.: Summary of reduction of cytokine/chemokine by the specific inhibitors
+++ extremely effective; ++ very effective; + effective; ~ tendency; - no effect 
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4. Discussion
Influenza A viruses are highly contagious RNA viruses and in humans the main 
targets are the epithelial cells of the respiratory tract [25]. In general influenza viruses 
cause acute infections which generally lead to a self-limiting disease [109], and do 
not spread further than the respiratory tract [110, 111]. Symptoms such as chills, 
fever, aches, malaise, sore throat, nasal congestion and pulmonary complications 
are common [113, 114]. However, other possible risks of complications and death 
are greatly increased in young children and older people [109, 111, 116, 117].
Reports of highly pathogenic influenza virus (HPIV) infections however, have shown 
more severe symptoms including progressive primary or secondary viral pneumonia 
[109, 118], extensive pulmonary oedema, acute respiratory distress syndrome 
(ARDS), alveolar haemorrhage, lymphopenia and multiple organ failure [109, 119]. 
Severe lung inflammation due to cytokines (i.e. TNF-, IFN/, IL-1, IL-8 and IL-6), 
has been associated with the pathogenesis of the disease and are mainly 
responsible for the systemic symptoms observed, like fever and myalgias [114, 115, 
119, 121, 125-127, 286].
Despite large immunisation programs, influenza A virus is still a considerable cause 
of morbidity and mortality worldwide and responsible for major epidemic outbreaks of 
influenza every year [290]. They have been responsible for the most devastating 
pandemic outbreaks of the last century, in 1918, 1957 and 1968, costing millions of 
human lives [3, 126, 291]. Avian Influenza virus (AIV) has also had a severe impact 
on the poultry industry worldwide which has resulted in serious economic loses.
Although it was previously accepted that AIV could not directly infect humans the 
emergence of HPAIV of the H5 and H7 subtype and specially outbreaks of the 
subtype (H5N1), which have crossed the species barrier into humans with high case 
fatality rates, has brought about deep concerns and the need of more readily 
available and effective anti-viral therapies [126, 290, 292-296].
Antiviral drugs amantadine and rimantadine, M2 ion channel protein inhibitors, 
reduce the duration of symptoms of clinical influenza, but the rapid appearance of 
drug-resistant variants coupled to major side effects have been reported [12, 277, 
278, 297]. Innovative sialic acid analogues, neuraminidase inhibitors, zanamivir and 
oseltamivir, have shown prophylactic and therapeutic effects, however due to the 
extremely high mutation rate of influenza viruses, inevitable virus resistance will 
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appear as has already been reported [106, 275]. Vaccination is yet another option, 
but again, due to constant changes in viral proteins this calls for annual adaptation 
and in the possible surging of a pandemic situation, the appropriate vaccines would 
not be produced in time [232, 279] to avoid a major disaster.
In view of these alarming reports, an understanding of the molecular mechanisms 
responsible for virus-induced inflammatory responses and viral replication in the lung 
could provide new approaches for therapeutic targeting during an influenza virus 
infection [12, 232]. 
As previously mentioned, influenza A virus (IAV) is capable of inducing activation of 
many different signalling pathways, in infected cells such as the MAPK family 
members [133, 134], including the classical Raf/MEK/ERK (MAPK) signalling 
cascade, the NF-B, the Jun N-terminal kinase (JNK) and the p38 [128]. Also other 
pathways have recently been found to also be activated by IAV such as PI3K and 
IRF3/7 [281]. Most of these pathways have been reported to act as antiviral 
mechanisms by promoting host immune responses (i.e. JNK, NF-B, IRF3/7, etc) 
[133, 232] whereas others are mainly/also linked in support of efficient virus 
replication (Raf/MEK/ERK and also NF-B) [128, 132, 138, 182, 186, 234].
Taking all this into account, the present work aimed to deal with these known facts 
and propose to modulate two pathways, the NF-B and the Raf/MEK/ERK, essential 
for virus replication and cytokine expression, by using specific inhibitors, with the 
intent of simultaneously reducing virus titres and virus-induced cytokines. The 
purpose was to broaden the available knowledge on therapeutic strategies to control 
and cure influenza virus-induced disease.
4.1. Bay 11-7082 can inhibit virus-induced NF-B activation in A549
Infection of cells with IAV has been reported to lead to activation of NF-B pathway 
either by over-expression of viral proteins such as the viral haemagglutinin (HA), 
nucleoprotein (NP) or M1 proteins [222, 223] or by the virus itself [232]. Also, studies 
using influenza virus-induced NF-B promoter-luciferase-reporter gene assays 
showed decrease in activity in cells co-expressing trans-dominant negative mutants 
of IKK2 or IB, upstream activators of NF-B [138]. Many reports on influenza-
induced activation of NF-B have been correlated to increase in expression of pro-
inflammatory factors, either by over-expression of chemokines such as IL-8 and 
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RANTES [135, 232] or in another study by enhanced NF-B binding to NF-B 
elements of the promoters of IFN and IL-29 genes [233], or by virus-induced IFN
promoter studies [71, 138]. Since many antiviral and pro-inflammatory cytokines are 
known to be controlled by the NF-B transcription factor [128, 189-192, 222] this 
pathway seems to play a role in the immune response, in the context of influenza 
virus infection. However, recent studies have shown that pre-activated NF-B in cells 
led to enhanced influenza virus replication, whereas in cells where NF-B was 
impaired, virus titres were significantly lower, demonstrating that the activation of this 
pathway is also somewhat important for efficient viral propagation [138, 139, 234]. 
In view of this I set out to modulate this pathway with the aim of reducing both virus 
replication as well as virus-induced cytokine production simultaneously.
Having ensured that treatment with Bay 11-7082 (25M) inhibitors did not affect 
A549 cell viability (Figure 3.1), tests on the NF-B activity, using a specific 
oligonucleotide ELISA based method, demonstrated that both FPV (Figure 3.2.1(A)) 
and PR8 (Figure 3.2.1(B)) infection lead to NF-B activation in these cells and that 
this up-regulation could be effectively reduced by the specific IKK-inhibitor (Bay)
(70% reduction in FPV and 80% in PR8 infected cells). This stood in agreement with 
the published articles mentioned above. 
4.2. Bay 11-7082 can inhibit virus titres in in vitro cell cultures as well as in vivo
Although there is consensus in that, infection of cells with IAV virus leads to NF-B 
activity, even though the virus NS1 protein can limit this activation [71], the same 
does not apply to the effects of this activity on virus replication. There have been 
contradictory reports on the importance/necessity of NF-B activity for efficient 
influenza virus propagation [138, 139, 232]. 
Using the A549 system, in the current study, with the specific IKK inhibitor (Bay at 
25M) (Figure 3.2.2) it was clear that the inhibition of this pathway greatly attenuated 
virus replication. This was true for both the avian (FPV – 50% reduction) and human 
(PR8 – 80% reduction) viruses analysed in these experiments.
Some of the reports already mentioned above have also dealt with NF-B inhibitors 
in their systems. Nimmerjahn et al. (2004) has previously shown by using another 
NF-B inhibitor (Bay 11-7085), that A/FPV/Bratislava virus titres are greatly reduced 
in A549 cells. Bernasconni et al. (2005), on the other hand, using the A/WSN/33 
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influenza virus and an alternative NF-B inhibitor, a cyclopentenone prostanoid 
(delta12-PGJ2), the drug was unable to show a decline in virus titres. Mazur et al.
(2007), very recently has also demonstrated using the acetylsalicylic acid (ASA) and 
Bay 11-7085, as NF-B inhibitors, in A549 cells and different influenza viruses that 
this pathway is required for efficient viral propagation.
A549 cells are human alveolar epithelial carcinoma cells, and are generally 
considered an artificial system. Therefore I decided to analyse mice primary alveolar 
epithelial cells (AECs) to get a closer look into a more natural system and also to 
analyse the correlation between these two in vitro systems (A549 and AECs). 
After performing viability tests on AECs to determine the non toxic concentration for 
Bay (15M) (Figure 3.6) further analysis were conducted by infection and treatment. 
The tests on AECs infected with FPV or PR8 treated with the Bay inhibitor (15M) 
confirmed the earlier results in A549 cells. Analysis of the virus (FPV and PR8) titres 
from supernatants demonstrated significant reduction (FPV ~ 40% reduction and 
PR8 ~ 85% reduction) at both 24 and 32h p.i. upon inhibitor treatment, compared to 
DSMO (solvent) treated cells (Figure 3.8 (A) and (B)). 
The idea that inhibition of the NF-B pathway could also possibly lead to reduction of 
virus titres in vivo, prompted me to study this model further using C57BL/6 mice. The 
results clearly demonstrate a significant drop in virus titre (~60%) at day 2 and day 5 
p.i. in C57BL/6 mice, treated daily with the Bay inhibitor, when compared to DMSO 
mock treated (Figure 3.14).
The use of specific NF-B inhibitors in reducing influenza A virus titres in vivo has 
also just recently been shown by Mazur et al. (2007), using acetylsalicylic acid (ASA). 
Although in this study I used a different NF-B inhibitor, Bay 11-7082, the data 
observed here confirm these newly published results. 
Many viruses have been reported to induce NF-B activation through different 
mechanisms [129, 193]. Some viruses, such as HTLV can lead to constitutively 
activated IKK complex and therefore NF-B activity, shown in chronically HTLV-1-
infected myeloid cells [298]. Other viruses, have recognized specific proteins like the 
LMP-1 oncoprotein of EBV (human  herpesvirus) and the HBx polypeptide of HBV 
(hepatitis B virus), which mediate NF-B activation through IB phosphorylation and 
degradation [299, 300] leading to the clear translocation of NF-B complexes thereby 
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trans-activating responsive NF-B genes. These effects have also been shown to 
have a supportive effect in the virus replication strategies.
This current report clearly demonstrates, by testing different in vitro cell systems as 
well as in vivo mice data that blocking the NF-B pathway can effectively be used to 
reduce influenza A virus propagation. 
4.3. U0126 can inhibit virus-induced the Raf/MEK/ERK activity in A549 cells
All known MAPK family members have been shown to be activated by influenza virus 
infection of cultured cells [132-134], amongst these the classical Raf/MEK/ERK 
(MAPK) signalling cascade, which is of interest to this work. As previously 
demonstrated activation of this pathway has mainly been linked to efficient influenza 
virus propagation [132, 182, 186].
In agreement with these earlier findings, the studies here (Figure 3.3.1.A and 3.3.1.B) 
demonstrate that both avian (FPV) as well as human (PR8) viruses were able to lead 
to ERK activation in human alveolar epithelial (A549) cells, showing a gradual 
increase over time, whereas this activity was dramatically decreased (~80%) when 
administering the specific MEK inhibitor, U0126 (50M). Previous tests on A549 cell 
viability (by MTT assay) had demonstrated no toxic effect of treatment with U0126 at 
50M (Figure 3.1).
4.4. U0126 can inhibit virus titres in in vitro cell cultures as well as in vivo
Previous reports using different cell lines (MDCK and 293T) and different influenza 
viruses (WSN and FPV), subjected to U0126 MEK inhibitor treatment have 
demonstrated the importance of this pathway for efficient virus propagation [132]. 
Also others have shown (in cell lines) through the modulation of this pathway, by 
using dominant-negative mutants of ERK and Raf, that both influenza A and B 
replication can be greatly reduced [182]. In contrast cells expressing active mutants 
of Raf led to enhanced virus production [182, 186]. 
From the current work it was also evident that inhibition of ERK activity in A549 cells, 
using the specific MEK inhibitor U0126 (at 50M), effectively reduced virus titres 
(FPV and PR8 by ~ 60%) (Figure 3.3.2), as seen in a time course analysis. Results 
from infected (FPV and PR8) mice primary alveolar epithelial cell (AEC) experiments 
treated with U0126 (40M) analysed up to 32h p.i. (Figure 3.8), still stand in 
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agreement (FPV by ~ 60% and PR8 by ~ 85%) with the effect observed in A549 
cells. To add credibility to the notion that the observed effect was not yet another 
artificial in vitro system approach. PR8 infected C57BL/6 mice showed similar 
reduction in virus titres both at 2 (~ 95%) and 5 day p.i. (50%), when treated daily 
with U0126 via intraperitoneal injection, compared to mock treated mice.
Previous in vivo work with U0126 in a mouse asthma model has reported that this 
inhibitor reduced ovalbumin (OVA)-induced phosphorylation of ERK and that it could 
have therapeutic potential for the treatment of airway inflammation [288]. Other 
studies in mice have also used the U0126 to successfully attenuate the behaviour 
response to high dose intrathecal morphine [301].
Dependency of virus propagation on the Raf/MEK/ERK pathway has also recently 
been shown in influenza virus infections in vivo using transgenic mice with a 
constitutively active form of Raf in the alveolar epithelial cells. It was apparent that 
influenza viruses almost exclusively replicated in cells carrying the transgene as 
opposed to the wild type animals where influenza viruses replicated mostly in the 
bronchial epithelial cells [186].
These observed effects are not unique for influenza viruses other viruses have also 
demonstrated dependency on this pathway for efficient propagation [302]. In a 
murine coronavirus mouse hepatitis virus (MHV) it was shown that the MEK inhibitor 
U0126 could reduce virus progeny production in different cells tested [303]. In 
another study using a different ERK/MAPK inhibitor, PD98059, it was also 
demonstrated the importance of this pathway for efficient Visna virus replication [302, 
304].
In view of these results I could ascertain that the aim of targeting influenza A virus 
reduction in vivo by inhibiting the Raf/MEK/ERK pathway was therefore successfully 
achieved. 
4.5. Bay 11-7082 and U0126 can decrease influenza A virus-induced cytokine 
production in in vitro cell cultures as well as in vivo
It has been previously shown that influenza A virus can induce cytokine expression 
both in vitro as well as in vivo [120, 238-244, 305]. It has also been postulated that in 
case of HPAI viruses the increased in observed pathogenesis of the disease could 
be due to increase and/or deregulated immune responses leading to 
hypercytokinaemia [111, 114, 115, 119, 120]. It is known that the expression of many 
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cytokines, including IFN, is modulated by NF-B activation [128, 189-192]. Although 
the Raf/MEK/ERK pathway in the context of IAV replication is generally linked to pro-
viral mechanisms [132, 181], it has been shown in another study that this pathway 
can also modulate IL-8 cytokine production [180]. We and others have shown that 
influenza viruses are able to activate both NF-B as well as Raf/MEK/ERK pathways 
[132, 139, 181, 231], therefore the aim now was to analyse expression of important 
cytokines and chemokines linked to immune regulation upon influenza virus infection 
(IL-8, MCP-1, IL-6, RANTES and IFN) and to determine whether these virus-
induced cytokine/chemokines could be decreased by application of the specific 
inhibitors.
Expression profiles of cytokines/chemokines varied depending on the virus used. In 
A549 cells, FPV had no effect on IL-8, IL-6 and MCP-1, but lead to an increase in 
RANTES production (Figure: 3.3.1.) whereas PR8 was able to induce IL-8 and IL-6, 
and suppressed RANTES and MCP-1 expression. What was consistent in all results 
was that both inhibitors (Bay and U0126) were able to successfully reduce 
cytokine/chemokine production. Also, in agreement with the report from Kuderer et 
al. [180], it was evident that IL-8 was mainly dependent on the Raf/MEK/ERK 
pathway since the U0126 was a better inhibitor than Bay 11-7082.
The results observed in A549 cells are in agreement with previous cell culture studies 
on BEAS-2B or BEC NCI-H292 (bronchial epithelial cell line) or A549 cells, where IL-
8 has been shown to be induced by H3N2 viruses [135, 232, 241]. Also IL-8, MCP-1 
and RANTES production have been described upon IVA (H3N2 or H1N1) infection 
[306-308]. Another study using human middle ear epithelial cells also identified IL-8, 
MCP-1, RANTES and TNF- as up-regulated in an influenza virus infection [309].
Still in A549 cells I was unable to detect any measurable amounts of IFN upon FPV 
or PR8 infection. In contrast, the delNS1 virus (a mutant PR8 with deleted NS1 
segment), used as a positive control here, was able to significantly induce secretion 
of IFN (Figure 3.4.2). This is in agreement with several reports demonstrating that 
the IAV NS1 protein has been associated with down-regulation or limited production 
of IFN [66, 67, 137, 230, 246, 310], which at least in part, might be due to limiting 
NF-B activation [71].
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In primary mice cell (AEC) experiments (Figure 3.9.1) FPV was shown to suppress 
KC (the mouse analogue for human IL-8), had no effect on MCP-1 or IL-6 secretion 
but led to a slight increase in RANTES production at 10h p.i.. These results were 
somehow in agreement with the results see in the A549 tests.  PR8, however, was 
able to increase MCP-1, IL-6, had no effect on RANTES, and decreased KC as 
compared to mock at 10hp.i.. In the case of PR8 in AECs it was evident that some 
cytokines were differentially regulated compared to A549 cells where IL-8 was 
induced and MCP-1 suppressed. Again what was visible in AECs, was that both Bay 
(IKK inhibitor) as well as U0126 (MEK inhibitor) were able to significantly reduce 
cytokine production to background levels for both viruses tested, with exception to 
RANTES. In the case of RANTES, the values identified were almost below the 
detection limit, proving it difficult to observe any statistical differences. 
IFN evaluation (Figure 3.9.2) of infected AECs showed that FPV was able to induce 
significant IFN production whereas PR8 lead to a very slight increase. As seen 
before in A549 cells the delNS1 virus was capable of inducing very high IFN
secretion (2867pg/ml), again demonstrating the importance of the NS1 protein in viral 
defence. In this study the Bay inhibitor was the main down-regulator of the viral-
induced IFN expression, as would be expected, since IFN production seems to be 
regulated by NF-B, IRF3/7 and AP-1 transcription factors [69, 128, 136].
It is also important to point out that the observed increase in IFN in AECs upon viral 
infection was not in accordance with the results observed in A549 cells, even though 
the FPV- and PR8-induced cytokine production was relatively low compared to the 
delNS1 virus control. This alerts to the fact that one should take care to correlate 
results from “artificial” cell culture experiments to what can actually occur in a natural 
infection.
In a study, comparing different cell systems (epithelial cells/macrophages) with IAV 
infection, it was demonstrated that macrophages, in this case, were able to 
significantly increase IFN production as compared to epithelial cells [231]. Other 
reports comparing H5N1 versus H1N1 in human primary alveolar epithelial cells were 
able to show very significant increases of IFN production from H1N1-infected cells, 
even though in comparison the H5N1 viruses all led to much higher induction than 
the H1N1 [240]. Also previous data from Matikainen et al. [246] show that pre-
stimulation of A549 cells with IFN- or TNF- can induce increase of IAV-induced 
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IFN as well as other cytokines, leading one to acknowledge the idea that in an in 
vivo situation where the environment includes a complex of different cell types and 
signalling events, the outcome could probably be very different to what one observes 
in a simple cell culture system, and that extrapolating concluding remarks is very 
risky. 
For this reason in vivo studies were conducted in this work to analyse possible 
differences from cell culture experiments (A549/AECs) and to approach a more “real” 
situation. 
Results from the in vivo infection (with PR8 at LD50) showed that, TNF- (Figure 
3.15) at day 2 p.i. was significantly increased in PR8-infected versus mock-infected 
C57BL/6 mice, whereas there were no significant differences observed at day 5. 
IFN was shown to be significantly increased for both DMSO and solvent treated and
infected groups compared to DMSO and solvent treated mock-infected mice, 
respectively, at day 2 and 5 p.i. (Figure 3.16). All other cytokines tested (KC, MCP-1, 
IL-6 and RANTES) (Figure 3.17 and 3.18) were found significantly increased in PR8-
infected versus mock infected mice at day 5 p.i., with exception to KC in the infected 
and DMSO treated group, although the tendency to increase was present. 
It has to be mentioned that the number of mice used for these experiments was 
indeed very low (n=3), and in some cases (for day 5 experiments) the control 
uninfected mice numbers were actually only 2. Due to the obvious ethical reasons, 
and the fact that these experiments were just to demonstrate a proof of principle, 
minimal mice amounts were used. For this reason also, the observed standard 
deviations were pretty high, and as a consequence the statistical analysis of the p-
value was sometimes not significant/relevant.
Regarding the inhibitor effects in the in vivo study, Bay was able to significantly 
decrease IFN expression, at day 2 p.i., and the tendency at day 5 was still there. It 
was also able to significantly decrease MCP-1, IL-6, and RANTES at day 5 p.i., and 
although the decrease for KC was not significant, the trend to decrease was noted. 
The U0126, on the other hand, showed a significant inhibition on PR8-induced TNF-
release, observed at day 2 p.i., but this effect was lost at day 5, whereas RANTES 
was significantly reduced at day 5 p.i.. U0126 also demonstrated a tendency for 
decreasing virus-induced cytokine production for most of the other cytokines 
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(IFNKC, MCP-1 and IL-6), but due to the limited number of samples analysed, the 
standard deviations only permit speculation.
One can also speculate on the correlation between virus titres and cytokine
induction. In general U0126 seems to reduce virus titres better than Bay, whereas 
Bay seems to be better at cytokine reduction. This might reflect that most cytokines 
are NF-B-dependent, and that the weaker cytokine reduction by U0126 is maybe 
mostly due actually to the reduction of virus titre.
Reports on influenza A virus induced cytokines are very heterogeneous depending 
on viruses used, whether the study was conducted using cell lines, primary cells or in 
vivo experiments. Studies from primary cells experiments, whether macrophages, 
monocytes or epithelial cells have shown all these cytokines/chemokines to be 
induced by, one influenza virus or another [237-240, 289, 311]. in vivo experiments,
using different virus strains, have also confirmed induction of all the cytokines studied 
in this report (IL-8/KC, MCP-1, IL-6, RANTES IFN and TNF-) [242, 254, 312-314].
In my study I have compared different in vitro and in vivo systems with the same 
viruses and treatments. 
It was interesting to observe different cytokine induction from the different systems 
(A549/AECs) in this study. For example the IL-8 was found to be up-regulated in 
PR8-infected A549 cells, whereas in AECs the virus suppressed this cytokine, 
compared to mock infected cells. Curiously the same effect was observed in other 
studies where IL-8 was shown to be induced in H3N2 virus-infected A549 cells, [241]
and BEAS-2B cells [135], whereas Sprenger et al. [238] and Hofmann et al. [237], 
showed decrease in IL-8 in human primary monocytes or macrophages, respectively, 
when using the PR8 virus. In a study conducted in mice Wareing et al. [242] also saw 
the same suppression or no effect in KC induction upon influenza virus infection.
Studies on the different pathways linked to induction of different 
cytokine/chemokines, have also shown some interesting data. Production of IFN, 
RANTES, IL-8, IL-6 and TNF- has been shown to be NF-B-dependent by different
authors using different systems [71, 196, 232, 315]. Whereas IL-8, MCP-1, IL-6 and 
also TNF- in other reports, have been linked to the activity of the Raf/MEK/ERK 
pathway [135, 283]. Still other pathways are also found to be implicated in the 
production of these cytokines, such as the p38 MAPK in IAV-induced production of 
RANTES, IL-8 and TNF- [134, 135, 289, 308]; and the AP-1/JNK pathway in IAV-
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induced production of RANTES as well [134, 308] or even specifically the PI3K 
activation pathway on the influence of RANTES and IL-8 production [135].
In this study, as was expected, the NF-B pathway was implicated in all the 
cytokine/chemokines tested, as seen by applying the inhibitor Bay 11-7082 to in vitro
infected cell cultures (A549/AECs) or in vivo (C57BL/6 mice). Generally the Bay 
inhibitor always demonstrated a stronger effect at decreasing cytokine/chemokine 
production compared to the U0126 inhibitor, with exception to IL-8 in A549 cells and 
TNF- in in vivo mice experiments. It was evident that the Raf/MEK/ERK was highly 
implicated in IL-8 production especially in A549 cells where the U0126 treatment of 
infected cells led to a very significant reduction of this chemokine. This effect was still 
apparent in AECs and in vivo experiments although not as spectacular. In fact all the 
cytokines tested in this work were able to be suppressed by inhibiting this pathway 
(Raf/MEK/ERK). This is the first time that this pathway, Raf/MEK/ERK, has been 
implicated in cytokine/chemokine production in the context of influenza A virus 
infection with exception to IL-8 production which had been shown by Guillot et al.
[135]. This discovery was also evident in the in vitro (A549/AECs) as well as the in 
vivo experiments (C57BL/6 mice).
Altogether, I was able to demonstrate that cytokines/chemokine (KC, MCP-1, IL-6, 
RANTES, IFN and TNF-) were induced by influenza A virus infection (FPV and 
PR8) in in vitro (A549/AECs) as well as in vivo (with PR8) and that this induction 
could be reduced by the specific IKK- (Bay 11-7082 for NF-B) or/and MEK-inhibitor 
(U0126 for Raf/MEK/ERK), in many cases to background levels, in all systems 
tested. It was also apparent that different systems lead to differential induction of
cytokines/chemokines, as seen mainly by IL-8, MCP-1 and IFN in A549 cells versus 
AECs and in vivo studies, and in the case of RANTES between in vitro PR8-infection 
and in vivo results. 
4.6. Both FPV and PR8-induced nuclear RNP export is efficiently blocked by 
Bay 11-7082 and U0126 in A549 and AECs.
Influenza A virus genome is composed of 8 segments of ssRNAs of negative polarity 
which are associated to viral polymerases (PA, PB1 and PB2) and nucleoprotein 
(NP) forming thus the ribonucleoprotein (RNPs). The virus is replicated in the nucleus 
of the infected cell and late in the replication cycle the viral genome forms the RNP 
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complexes which have to be efficiently exported from the nucleus into the cytoplasm 
to be able to be packaged into progeny virions at the cell surface (ref). This step is of 
course very important in influenza virus replication. As both, NF-B and ERK
pathway activation have been associated with efficient viral nuclear RNP export [132, 
181, 234], I decided to confirm these findings in our A549 system, by making use of 
our specific IKK and MEK inhibitors. Results demonstrate that in A549 cells both 
avian (FPV) as well as human (PR8) influenza virus showed nuclear RNP export 
whereas upon inhibitor treatment (with either Bay or U0126), the RNP export was 
significantly impaired as seen at 10h p.i. (Figure 3.5.1 and 3.5.2). These results add 
to the already published data, confirming that the activation of both NF-B as well as 
Raf/MEK/ERK pathway is necessary for efficient viral nuclear RNP export. 
In AECs both FPV and PR8 also showed nuclear RNP export at 10h p.i. but upon 
inhibitor treatment (with Bay or U0126), the viral RNP was mainly blocked in the 
nucleus (Figure 3.5.1 and 3.5.2). This excludes the idea that the observed effect in 
could be an artefact only seen in established cell lines, even though confirmed by 
others in other cell lines [132, 181, 234]. Since AECs are primary cells one can 
speculate that this effect reflects the in vivo situation.
The mechanism for this effect has been suggested to be partially dependent on the 
activity of viral nuclear export protein NEP/NS2 [44, 132]. Other findings suggest that 
this might be dependent on viral induction of the pro-apoptotic factors, such as 
Caspase 3 [316] and NF-B-dependent tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) and FasL [138]. In support of this NF-B dependency, Mazur 
et al. (2007) also just recently showed that ASA (an NF-B inhibitor) was able to also 
block virus-induced RNP export from the nucleus of A549 cells.
Although the aim of this study was not concerned with explaining the molecular 
mechanisms of this effect, it was interesting to observe that during AEC infection 
studies, cell viability was increased in infected cells treated with the IKK inhibitor 
(Bay) compared to the infected DMSO treated cells (Figure 3.7 (A) and (B)). This was 
observed for both viruses (FPV and PR8), which would agree with the above 
suggestion, that virus-induced NF-B activity leads to induction of apoptosis, and that 
by specifically inhibiting this pathway, one can down-regulate NF-B-dependent virus 
replication and thereby virus-induced cell destruction.
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4.7. Combination treatment does not enhance individual inhibitor-induced 
decrease in virus titres
With the aim of further reducing virus propagation with combination treatment and 
thereby possibly reducing the concentration necessary of the individual inhibitors for 
this effect, studies were conducted in A549 cells and AECs. The idea was that by 
reducing the amount of inhibitor treatment needed, one would reduce possible 
intolerance of the drugs or side effects that could later be observed in vivo while at 
the same time still producing the same (or better) effect (reducing virus 
titres/cytokines). Results from selected non-toxic inhibitor “cocktails” (Bay-
15M/U0126-30M and Bay-10M/U0126-30M) showed no significantly enhanced 
decrease of virus titres when comparing to results with single inhibitor treatment in 
A549 cells (Figure: 3.12). This idea was then completely abandoned after results 
from viability assays in AECs demonstrated a significant toxic effect even when 
applying low concentrations of both inhibitors (Figure: 3.13).
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5. Conclusions
In the present work I show that influenza A virus infection can strongly induce NF-B 
as well as Raf/MEK/ERK pathway activity, in human alveolar epithelial A549 cells. 
The different viruses used in our study avian FPV as well as human PR8 led to 
different kinetics as well as different activity intensities of these pathways. Inhibition 
of these pathways using a specific IKK-inhibitor (for the NF-B pathway) or MEK 
inhibitor (for the Raf/MEK/ERK pathway) could efficiently reduce this virus-induced 
activity in A549 cells. 
Infection studies using the specific inhibitors Bay and U0126, demonstrated for the 
first time that these pathways (NF-B and Raf/MEK/ERK, respectively) are required 
for efficient virus propagation, not only in human alveolar epithelial A549 cells but 
also in mice primary alveolar epithelial cells (AECs) and in vivo in C57BL/6 mice, as 
determined in titration by FFU assay.
The role of NF-B pathway in influenza A virus infection has been a little 
controversial. In general NF-B activation is associated with the cellular antiviral 
response to influenza infection. Aside from this accepted view, it has also been 
recently considered as a requirement for virus infectivity [138, 139, 234]. Other 
studies have indicated that viral replication is independent from the ability of the virus 
to activate NF-B in infected cells [232].
My data clearly indicates and supports the former idea, that influenza A virus 
infection not only activates NF-B transcription factor, but also that this activity 
promotes efficient virus replication.
As to the Raf/MEK/ERK pathway, studies in influenza A virus infections point to a 
requirement of activity of this pathway for efficient virus propagation [132, 181, 182, 
186], whereas in this study for the first time it becomes evident that this pathway also 
affects host cell defence mechanisms, and that by inhibiting this pathway it is 
possible to reduce virus-induced cytokines as well as the predicted virus propagation.
In agreement also with previous studies I could demonstrate that upon virus infection 
cells will secrete different cytokines and that some of these cytokines can be NF-B 
dependently induced (IL-8, KC, MCP-1, IL-6, RANTES and IFN) as seen by using 
the Bay (IKK inhibitor) and/or Raf/MEK/ERK-dependent (IL-8, KC, MCP-1, IL-6, 
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RANTES and TNF-). This was apparent in all the models tested here, in the in vitro
cell cultures and in the mice in vivo experiments.
Influenza viruses follow a nuclear replication strategy and therefore late in their 
replication cycle the viral genome RNP has to be exported from the nucleus into the 
cytoplasm. Here it was shown for the first time in primary cells, using mice alveolar 
epithelial cells (AECs), that the viral-induced RNP export from the nucleus was 
significantly impaired upon treatment with either IKK or MEK inhibitors. Previous 
studies performed in different cell lines [132, 181, 234] have shown the same effect 
that was observed here in human alveolar epithelial cells (A549) and in mice primary 
cells (AECs).
The aim of this study was to modulate these two pathways with the purpose of 
decreasing virus replication as well as simultaneously decreasing virus-induced 
cytokine production. It can be safely said that this aim was achieved with success. 
It has to be added, however, that the final aim would be to target these pathways for 
antiviral therapy strategies. Studies conducted with HPIV have shown, in humans, 
primates and mice, that high viral loads as well as elevated pro-inflammatory factors 
are central to the pathogenesis observed in these infections [115, 119, 120, 254] and 
in a H5N1 study in pigs it was demonstrated that this virus was resistant to the effects 
of interferons and TNF- [294]. However, a recent report has highlighted the concern 
of targeting an essential mechanism of the organism in combating the disease, by 
showing that glucocorticoid (steroids, which show among other functions,
suppression of cytokines) treatment (given in the drinking water) of mice infected with 
HPAIV (H5N1) did not protect against death [317]. 
In the current report it is apparent that many pathways lead to redundant effects. The 
idea to target a specific pathway, which is necessary for virus replication as well as 
for immune regulation, seems logical in view of all the reported studies with HPIV 
infections. In the in vivo context, it is also evident that affecting a specific pathway will 
not totally block its overall effect on immune response mechanisms, but might be 
able to attenuate the “cytokine storm” seen with these HPIV strains. The aim here 
was not to deplete the natural/necessary immune response, but to diminish the virus-
induced hyper-induction of the inflammatory response which is a cause of the gravity 
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of this disease. Further studies could be extremely valuable for fine-tuning the effects 
of these drugs.
Although targeting a cellular factor brings about concerns as to the possible side 
effects raised from drug usage, local administration could probably be more, well 
tolerated [12]. Drugs targeting these pathways are already in current use, such as 
NF-B inhibitors like the common aspirin [203, 234, 318], and as for the 
Raf/MEK/ERK pathway, since chronic activation of this pathway is linked to several 
cancers [147, 148] there are many drugs under clinical trial for application in cancer 
therapy [148, 302].
Prospective studies
Many extra experiments could still be done to add to the available data so far 
achieved in this report, such as: (1) further studies with infected mice using the Bay 
and U0126 inhibitors, to study survival curves with these inhibitors; (2) attempting 
other viral strains for infection to compare pathology and cytokine induction in 
inhibitor treated versus untreated; (3) to analyse lung histology and cell population 
profiles in infected mice untreated compared to inhibitor treated mice.
Due to the time available further studies will have to be postponed. But the future 
prospects would be recommended, since the current report shows potential for 
aiming at influenza virus therapy.
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